0001171520-20-000375.txt : 20200813 0001171520-20-000375.hdr.sgml : 20200813 20200813160813 ACCESSION NUMBER: 0001171520-20-000375 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200813 DATE AS OF CHANGE: 20200813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ClearPoint Neuro, Inc. CENTRAL INDEX KEY: 0001285550 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 582394628 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34822 FILM NUMBER: 201099357 BUSINESS ADDRESS: STREET 1: 5 MUSICK CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9499006833 MAIL ADDRESS: STREET 1: 5 MUSICK CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: MRI INTERVENTIONS, INC. DATE OF NAME CHANGE: 20110714 FORMER COMPANY: FORMER CONFORMED NAME: SURGIVISION INC DATE OF NAME CHANGE: 20091106 FORMER COMPANY: FORMER CONFORMED NAME: SURGI VISION INC DATE OF NAME CHANGE: 20040331 10-Q 1 eps9162.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended June 30, 2020

Or

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from_____to _____

Commission file number: 001-34822

ClearPoint Neuro, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	58-2394628
(State or Other Jurisdiction	(IRS Employer
of Incorporation or Organization)	Identification Number)

5 Musick
Irvine, California	92618
(Address of Principal Executive Offices)	(Zip Code)

(949) 900-6833

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)

☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☑	Smaller reporting company ☑
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

As of August 10, 2020, there were 15,731,352 shares of common stock outstanding.

CLEARPOINT NEURO, INC.

TABLE OF CONTENTS

		Page Number

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	4
	Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019	4
	Condensed Consolidated Statements of Operations for the three months ended June 30, 2020 and 2019	5
	Condensed Consolidated Statements of Operations for the six months ended June 30, 2020 and 2019	6
	Condensed Consolidated Statements of Stockholders’ Equity for the six months ended June 30, 2020 and 2019	7
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4.	Controls and Procedures	28

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	29
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3.	Defaults Upon Senior Securities	29
Item 4.	Mine Safety Disclosures	29
Item 5.	Other Information	29
Item 6.	Exhibits	30

SIGNATURES		31

Trademarks, Trade Names and Service Marks

ClearPoint^®, ClearTrace^® and ClearPoint Neuro^® are trademarks of ClearPoint Neuro, Inc. Any other trademarks, trade names or service marks referred to in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are the property of their respective owners.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report contains “forward-looking statements” as defined under the United States federal securities laws. The forward-looking statements are contained principally in the section of this Quarterly Report entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements, expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

●

the COVID-19 pandemic and measures taken or that may be taken to combat the spread of the disease;

●

future revenues from sales of ClearPoint system products and services;

●

our ability to market, commercialize and achieve broader market acceptance for our ClearPoint system products; and

estimates regarding the sufficiency of our cash resources and our ability to obtain additional financing, to the extent necessary or advisable.

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.

You should refer to the section titled “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which we filed with the SEC on March 27, 2020 (the “2019 Form 10-K”) and in this Quarterly Report, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by the forward-looking statements contained in this Quarterly Report. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake to update any of the forward-looking statements after the date of this Quarterly Report, except to the extent required by applicable securities laws.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CLEARPOINT NEURO, INC.

(formerly MRI Interventions, Inc.)
Condensed Consolidated Balance Sheets

	June 30, 2020 (Unaudited)			December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	16,032,082		$	5,695,722
Accounts receivable, net		1,163,663			1,089,917
Inventory, net		3,598,980			3,240,218
Prepaid expenses and other current assets		537,940			357,227
Total current assets		21,332,665			10,383,084
Property and equipment, net		342,584			447,162
Operating lease rights of use		321,155			374,218
Software license inventory		506,800			504,400
Licensing rights		517,207			135,000
Other assets		12,438			82,573
Total assets	$	23,032,849		$	11,926,437

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,491,377		$	965,783
Accrued compensation		969,877			1,408,292
Other accrued liabilities		334,627			328,460
Operating lease liabilities, current portion		110,914			113,520
Deferred product and service revenue		620,126			1,016,892
Paycheck Protection Program loan payable, current portion		296,677			—
Total current liabilities		3,823,598			3,832,947
Accrued interest		—			959,659
Operating lease liabilities, net of current portion		227,714			276,669
Deferred product and service revenue, net of current portion		228,286			197,862
2020 senior secured convertible notes payable, net		16,814,099			—
2010 junior secured notes payable, net		—			2,072,583
Paycheck Protection Program loan payable, net of current portion		599,323			—
Total liabilities		21,693,020			7,339,720
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at June 30, 2020 and December 31, 2019		—			—
Common stock, $0.01 par value; 200,000,000 shares authorized; 15,512,687 shares issued and outstanding at June 30, 2020; and 15,235,308 issued and outstanding at December 31, 2019		155,127			152,353
Additional paid-in capital		117,640,195			117,173,984
Accumulated deficit		(116,455,493	)		(112,739,620	)
Total stockholders’ equity		1,339,829			4,586,717
Total liabilities and stockholders’ equity	$	23,032,849		$	11,926,437

See accompanying notes to Condensed Consolidated Financial Statements.

CLEARPOINT NEURO, INC.

(formerly MRI Interventions, Inc.)
Condensed Consolidated Statements of Operations
(Unaudited)

	For The Three Months Ended June 30,
	2020			2019
Revenues:
Product revenues	$	1,593,070		$	2,194,194
Service and other revenues		884,712			412,204
Total revenues		2,477,782			2,606,398
Cost of revenues		640,805			1,030,316
Research and development costs		822,301			697,803
Sales and marketing expenses		1,124,378			1,143,056
General and administrative expenses		1,365,084			1,028,291
Operating loss		(1,474,786	)		(1,293,068	)
Other income (expense):
Other income, net		10,851			1,693
Interest expense, net		(197,113	)		(259,020	)
Net loss	$	(1,661,048	)	$	(1,550,395	)
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.11	)	$	(0.13	)
Weighted average shares outstanding:
Basic and diluted		15,504,169			12,302,667

See accompanying notes to Condensed Consolidated Financial Statements.

CLEARPOINT NEURO, INC.

(formerly MRI Interventions, Inc.)
Condensed Consolidated Statements of Operations
(Unaudited)

	For The Six Months Ended June 30,
	2020			2019
Revenues:
Product revenues	$	3,696,455		$	4,358,148
Service and other revenues		1,896,921			720,767
Total revenues		5,593,376			5,078,915
Cost of revenues		1,558,141			1,916,798
Research and development costs		1,651,829			1,282,343
Sales and marketing expenses		2,422,972			2,183,769
General and administrative expenses		2,643,592			1,961,322
Operating loss		(2,683,158	)		(2,265,317	)
Other income (expense):
Other income, net		6,131			7,322
Interest expense, net		(1,038,846	)		(513,125	)
Net loss	$	(3,715,873	)	$	(2,771,120	)
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.24	)	$	(0.24	)
Weighted average shares outstanding:
Basic and diluted		15,471,222			11,676,872

See accompanying notes to Condensed Consolidated Financial Statements.

CLEARPOINT NEURO, INC.

(formerly MRI Interventions, Inc.)

Condensed Consolidated Statements of Stockholders’ Equity
(Unaudited)

For The Six Months Ended June 30, 2020
					Additional
	Common Stock				Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balances, January 1, 2020		15,235,308	$	152,353	$	117,173,984		$	(112,739,620	)	$	4,586,717
Issuances of common stock:
Share-based compensation		9,696		97		227,871			—			227,968
Warrant exercises (cashless)		262,145		2,621		(2,621	)		—			—
Net loss for the period		—		—		—			(2,054,825	)		(2,054,825	)
Balances, March 31, 2020		15,507,149		155,071		117,399,234			(114,794,445	)		2,759,860
Issuances of common stock:
Share-based compensation		5,538		56		240,961			—			241,017
Net loss for the period		—		—		—			(1,661,048	)		(1,661,048	)
Balances, June 30, 2020		15,512,687	$	155,127	$	117,640,195		$	(116,455,493	)	$	1,339,829

For The Six Months Ended June 30, 2019
					Additional
	Common Stock				Paid-in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balances, January 1, 2019		11,018,364	$	110,183	$	108,600,405		$	(107,199,586	)	$	1,511,002
Cumulative adjustment for adoption of new accounting standard		—		—		—			(244	)		(244	)
Issuances of common stock:
Share-based compensation		28,462		285		152,301			—			152,586
Warrant exercises		20,381		204		(204	)		—			—
Net loss for the period		—		—		—			(1,220,725	)		(1,220,725	)
Balances, March 31, 2019		11,067,207		110,672		108,752,502			(108,420,555	)		442,619
Issuances of common stock:
Share-based compensation		3,251		32		203,962			—			203,994
Warrant exercises		189,407		1,894		381,182			—			383,076
May 2019 private placement, net of offering costs of $94,162		2,426,455		24,265		7,403,583			—			7,427,848
Net loss for the period		—		—		—			(1,550,395	)		(1,550,395	)
Balances, June 30, 2019		13,686,320	$	136,863	$	116,741,229		$	(109,970,950	)	$	6,907,142

See accompanying notes to Condensed Consolidated Financial Statements.

CLEARPOINT NEURO, INC.

(formerly MRI Interventions, Inc.)

Condensed Consolidated Statements of Cash Flows
(Unaudited)

	For The Six Months Ended June 30,
	2020			2019
Cash flows from operating activities:
Net loss	$	(3,715,873	)	$	(2,771,120	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization		116,026			69,600
Share-based compensation		468,985			356,580
Amortization of debt issuance costs and original issue discounts		821,301			363,465
Amortization of lease rights of use, net of accretion in lease liabilities		49,782			51,255
Increase (decrease) in cash resulting from changes in:
Accounts receivable		(73,746	)		(137,931	)
Inventory, net		(313,476	)		(201,503	)
Prepaid expenses and other current assets		(180,712	)		(216,953	)
Other assets		70,134			11,899
Accounts payable and accrued expenses		93,347			716,222
Accrued interest		(959,661	)		—
Lease liabilities		(48,280	)		(50,285	)
Deferred revenue		(366,341	)		389,201
Net cash flows from operating activities		(4,038,514	)		(1,419,570	)
Cash flows from investing activities:
Acquisition of licensing rights		(441,341	)		(150,000	)
Net cash flows from investing activities		(441,341	)		(150,000	)
Cash flows from financing activities:
Proceeds from issuance of 2020 senior secured convertible notes, net of financing costs and discount		16,757,871			—
Proceeds from issuance of Paycheck Protection Program loan		896,000			—
Proceeds from private placement of common stock		—			7,522,010
Proceeds from stock option warrant exercises		—			383,075
Repayment of notes payable		(2,837,656	)		(1,975,000	)
Net cash flows from financing activities		14,816,215			5,930,085
Net change in cash and cash equivalents		10,336,360			4,360,515
Cash and cash equivalents, beginning of period		5,695,722			3,101,133
Cash and cash equivalents, end of period	$	16,032,082		$	7,461,648

SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for:
Income taxes	$	—		$	—
Interest	$	1,043,371		$	164,157

NON-CASH TRANSACTIONS:

During the six months ended June 30, 2020 Company recorded net sales of ClearPoint reusable components having an aggregate net book value of $47,686 that had previously been transferred from inventory to loaned systems, which are included in property and equipment in the accompanying condensed consolidated balance sheets. During the six months ended June 30, 2019, the Company recorded net transfers of ClearPoint reusable components having an aggregate net book value of $163,321 from loaned systems to inventory.

On January 1, 2019, the Company adopted the provisions of Topic 842 within the Accounting Standards Codification, which resulted in the establishment of operating lease right-of-use assets and operating lease liabilities, each in the aggregate amount of $480,395 (see Note 6).

In connection with the 2019 PIPE (see Note 7), the Company incurred approximately $94,000 of issuance costs that were unpaid and included in accounts payable at June 30, 2019.

See accompanying notes to Condensed Consolidated Financial Statements.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.	Description of the Business and Financial Condition

ClearPoint Neuro, Inc. (the “Company”) is a medical device company focused on the development and commercialization of technology that enables physicians to see inside the brain and heart using direct, intra-procedural magnetic resonance imaging (“MRI”) guidance while performing minimally invasive surgical procedures.

The Company’s ClearPoint^® system, an integrated system comprised of capital equipment and disposable products, is designed to allow minimally invasive procedures in the brain to be performed in an MRI suite. The Company received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) in 2010 to market the ClearPoint system in the United States for general neurological interventional procedures. The Company’s ClearTrace^® system is a product candidate that is designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. Although still a product candidate, the Company has reduced its efforts to commercialize the ClearTrace system.

On February 12, 2020, the Company changed its corporate name from MRI Interventions, Inc. to ClearPoint Neuro, Inc., pursuant to a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware. In addition, effective as of February 12, 2020, the Company’s Board of Directors adopted the Second and Amended Restated Bylaws, to reflect the name change of the Company. No other changes were made to the Company’s certificate of incorporation or bylaws. In connection with the Company’s name change, effective as of the opening of trading on February 12, 2020, the Company’s shares of common stock commenced trading on the Nasdaq Capital Market under the symbol “CLPT.”

COVID-19

On March 11, 2020, the World Health Organization characterized the spread of a novel strain of coronavirus (“COVID-19”) as a global pandemic, and on March 13, 2020, the President of the United States proclaimed that the COVID-19 outbreak in the United States constituted a national emergency. Continued widespread infection in the United States is a possibility. Extraordinary actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-19, including issuance of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations. These measures, while intended to protect human life, have led to reduced economic activity, including the postponement or cancellation of elective surgical procedures, which historically have represented approximately 80% of the number of surgical procedures using the Company’s ClearPoint system. Furthermore, the recessionary conditions on the financial markets and global economy caused by the COVID-19 pandemic could have a material adverse effect on the Company’s business, as hospitals postpone or reduce capital purchases and overall spending. The rapid development and fluidity of the situation precludes any prediction as to the ultimate impact COVID-19 will have on the Company’s business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-19 outbreak in the United States.

Liquidity

The Company has incurred net losses since its inception, which has resulted in a cumulative deficit at June 30, 2020 of $116 million. In addition, the Company’s use of cash from operations amounted to $4.0 million for the six months ended June 30, 2020 and $2.8 million for the year ended December 31, 2019. Since its inception, the Company has financed its operations principally from the sale of equity securities, the issuance of notes payable, product and service contracts and license arrangements.

As discussed in Note 7, in May 2019, the Company entered into a Securities Purchase Agreement with certain accredited investors under which such investors purchased 2,426,455 shares of the Company’s common stock at $3.10 per share (the “2019 PIPE), resulting in proceeds of approximately $7.5 million, before deducting offering expenses aggregating approximately $94,000.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

In addition, as discussed in Note 5, in January 2020, the Company entered into a Securities Purchase Agreement with two investors under which the Company issued to such investors an aggregate principal amount of $17.5 million of floating rate secured convertible notes (the “2020 Secured Notes”), resulting in proceeds, net of financing costs paid and payable, and a commitment fee paid to one of the investors, of approximately $16.8 million. From the net proceeds received from the issuance of the 2020 Secured Notes, which have a five-year term, the Company repaid and retired the 2010 Junior Secured Notes Payable (the “2010 Secured Notes”) that otherwise would have matured in October and November 2020.

Also, as discussed in Note 5, in April 2020, the Company received $896,000 in proceeds through a loan funded under the Payroll Protection Program as part of the CARES Act. Management’s plan during the period in which the Company is affected by the COVID-19 pandemic is to retain the Company’s employee base and, pending the ultimate duration and impact of the COVID-19 pandemic and by using the funds for the purposes described under the terms of the loan, consider whether to repay the loan in conformity with its terms or request that all or a portion of the loan, as applicable under its terms, be ultimately forgiven. However, there is no assurance that the Company would be successful in obtaining such forgiveness.

Based on the foregoing, in management’s opinion, cash and cash equivalent balances at June 30, 2020, when combined with the proceeds from issuance of the 2020 Secured Notes (after repayment of the 2010 Secured Notes) and receipt of the proceeds from the loan funded under the Payroll Protection Program, are sufficient to support the Company’s operations and meet its obligations for at least the next twelve months.

2.	Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2019 audited consolidated financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with United States Securities and Exchange Commission (“SEC”) rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2019 Form 10-K. The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for a complete set of financial statements. The results of operations for the three and six months ended June 30, 2020 may not be indicative of the results to be expected for the entire year or any future periods.

Inventory

Inventory is carried at the lower of cost (first-in, first-out method) or net realizable value. Items in inventory relate predominantly to the Company’s ClearPoint system. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for obsolete items and provides a reserve upon identification of potential obsolete items.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Intangible Assets

In June 2019 and February 2020, the Company entered into license agreements that provide rights to the Company for the development and commercialization of products in the functional neurosurgery field. Under the terms of those certain license agreements, the Company paid an aggregate $591,341 to the licensors upon execution of the license agreements for access to the underlying technologies and will make future payments based on the achievement of regulatory and commercialization milestones as defined in the license agreements.

In conformity with Accounting Standards Codification Section 350, “Intangibles – Goodwill and Other,” the Company amortizes its investment in the license rights described above over an expected useful life of five years.

Revenue Recognition

The Company’s revenues are comprised primarily of: (1) product revenues resulting from the sale of functional neurosurgical products, and drug delivery and biologic products; (2) product revenues resulting from the sale of ClearPoint capital equipment; (3) revenues resulting from the rental, service, installation, training and shipping related to ClearPoint capital equipment; and (4) clinical case support revenues in connection with customer-sponsored clinical trials. The Company recognizes revenue when control of the Company’s products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control.

Lines of Business; Timing of Revenue Recognition

Functional neurosurgery product, biologics and drug delivery systems product, and therapy product sales: Revenues from the sale of functional neurosurgery products (consisting of disposable products sold commercially and related to cases utilizing the Company’s ClearPoint system), biologics and drug delivery systems (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in non-neurosurgical procedures), are generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and are recognized at the point in time of delivery to the customer, which is the point at which legal title, and risks and rewards of ownership, along with physical possession, transfer to the customer.

Capital equipment sales

Capital equipment sales preceded by evaluation periods: The predominance of capital equipment sales (consisting of integrated computer hardware and software that are integral components of the Company’s ClearPoint system) are preceded by customer evaluation periods of generally 90 days. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment sales following such evaluation periods is recognized at the point in time the Company is in receipt of an executed purchase agreement or purchase order.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Capital equipment sales not preceded by evaluation periods: Revenue from sales of capital equipment not having been preceded by an evaluation period is recognized at the point in time that the equipment has been delivered to the customer.

For both types of capital equipment sales described above, the Company’s determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment.

Functional neurosurgery and related services: Revenues from functional neurosurgery and related services are recognized over the period of time such services are rendered.

Biologics and drug delivery services:

Outsourced technical clinical support of cases performed pursuant to customer-sponsored clinical trials:

Service Access Fees: For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by Company personnel during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service.

Procedure-Based Fees: The Company recognizes revenue at the point in time a case is attended by Company personnel.

Therapy services: The Company recognizes revenue for such services at the point in time that the performance obligation has been satisfied.

Capital equipment-related services:

Equipment service: Revenue from service of ClearPoint capital equipment previously sold to customers is based on agreements with terms ranging from one to three years and revenue is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for rental and service revenues because the Company transfers control evenly by providing a stand-ready service.

Installation, training and shipping: Consistent with the Company’s recognition of revenue for capital equipment sales as described above, fees for installation, training and shipping in connection with sales of capital equipment that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase order for the equipment. Installation, training and shipping fees related to capital equipment sales not having been preceded by an evaluation period are recognized as revenue at the point in time that the related services are performed.

The Company operates in one industry segment, and substantially all its sales are to U.S.-based customers.

Payment terms under contracts with customers generally are in a range of 30-60 days after the customers’ receipt of the Company’s invoices.

The Company provides a one-year warranty on its functional neurosurgery products, biologics and drug delivery systems products, and capital equipment products that are not otherwise covered by a third-party manufacturer’s warranty. The Company’s contracts with customers do not provide for a right of return other than for product defects.

See Note 3 for additional information regarding revenue recognition.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Net Loss Per Share

The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the entire amount of the Company’s outstanding common stock options and warrants, as described in Note 7, and the potential conversion of the 2020 Secured Notes, as described in Note 5, would be anti-dilutive.

Concentration Risks and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At June 30, 2020, the Company had approximately $7.9 million in bank balances that were in excess of the insured limits.

Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:

			June 30, 2020				December 31, 2019
Customer – 1			—				12%

Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		22%		—

Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		21%		—

Prior to granting credit, the Company performs credit evaluations of its customers’ financial condition, and generally does not require collateral from its customers. The Company will provide an allowance for doubtful accounts when collections become doubtful. The allowance for doubtful accounts at June 30, 2020 and December 31, 2019 was approximately $32,000 and $29,000, respectively.

The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Revenue Recognition

Revenue by Service Line

	Three Months Ended June 30,
	2020		2019
Products:
Disposable products:
Functional neurosurgery	$	1,049,015	$	1,690,122
Biologics and drug delivery		406,955		244,949
Therapy		21,300		17,830
Capital equipment		115,800		241,293
Total product revenue		1,593,070		2,194,194
Services:
Capital equipment and other		123,998		243,954
Biologics and drug delivery		760,714		168,250
Total service revenue		884,712		412,204
Total revenue	$	2,477,782	$	2,606,398

	Six Months Ended June 30,
	2020		2019
Products:
Disposable products:
Functional neurosurgery	$	2,733,424	$	3,294,767
Biologics and drug delivery		580,330		529,859
Therapy		78,800		17,830
Capital equipment		303,901		515,692
Total product revenue		3,696,455		4,358,148
Services:
Capital equipment and other		280,493		455,156
Biologics and drug delivery		1,616,428		265,611
Total service revenue		1,896,121		720,767
Total revenue	$	5,593,376	$	5,078,915

Contract Balances

Contract assets – Substantially all the Company’s contracts with customers are based on customer-issued purchase orders for distinct products or services. Customers are billed upon delivery of such products or services, and the related contract assets comprise the accounts receivable balances included in the accompanying condensed consolidated balance sheets.

Contract liabilities – The Company generally bills and collects capital equipment-related service fees at the inception of the service agreements, which have terms ranging from one to three years. The unearned portion of such service fees are classified as deferred revenue.

During the three and six months ended June 30, 2020, the Company recognized capital equipment-related service revenue of approximately $89,000 and $210,000, respectively, which was previously included in deferred revenue in the accompanying condensed consolidated balance sheet at December 31, 2019.

In September 2019, the Company entered into a Development Services Agreement with a customer under which the Company was entitled to bill the customer for an upfront payment of $127,600, of which $83,000 and $102,000 are included in deferred revenue in the accompanying June 30, 2020 and December 31, 2019 condensed consolidated balance sheets, respectively.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Also, in September 2019, the Company entered into a Letter of Intent, followed by a related Statement of Work (together with the Letter of Intent, the “Project Documents”) in November 2019, with a customer which is a stockholder and whose then Chief Operating Officer was a member of the Company’s Board of Directors (and was subsequently replaced with the customer’s Chief Development Officer), to commence a product development project. Under the terms of the Project Documents, the Company was entitled to bill the customer for: (a) an upfront, nonrefundable payment of $500,000; and (b) quarterly service fees of $500,000 commencing in the fourth quarter of 2019. In February 2020, the Company entered into a Supply Agreement and a Statement of Work (the “European SOW”) with a European affiliate of the customer. Under the terms of the European SOW, the Company was entitled to bill the customer on a quarterly basis, commencing in the first quarter of 2020, for service fees of $250,000. During the six months ended June 30, 2020, the clinical trials contemplated by the Project Documents and the European SOW were delayed as a result of the COVID-19 pandemic. As a result, the Company agreed to reduce such quarterly service fees by an aggregate of $100,000 and $200,000 during the three and six months ended June 30, 2020, respectively. The Company recognizes as revenue each of the upfront payments described in this paragraph in proportional relationship to the transaction prices of the performance obligations contained in the related agreements, and recognizes as revenue the quarterly service fees described in this paragraph as stand-by services beginning in the quarter such services commenced. Based on the foregoing, approximately $429,000 and $625,000 of the aggregate amount of all the payments described in this paragraph were included in deferred revenue in the accompanying condensed consolidated balance sheets at June 30, 2020 and December 31, 2019, respectively.

The Company offers an upgraded version of its software at no additional charge to customers purchasing a three-year systems service agreement. The transaction prices of the software and the service agreement are determined through an allocation of the service agreement price based on the standalone prices of the software and the service agreements. The transaction price of the software is recognized as revenue upon its installation and comprised approximately $143,000 and $172,000 of unbilled accounts receivable at June 30, 2020 and December 31, 2019, respectively.

Remaining Performance Obligations

The Company’s contracts with customers, other than capital equipment-related service agreements discussed below, are predominantly of terms less than one year. Accordingly, the transaction price of remaining performance obligations related to such contracts at June 30, 2020 are not material.

Revenue with respect to remaining performance obligations related to capital equipment-related service agreements with original terms in excess of one year and the upfront payments discussed under the heading “Contract Balances” above amounted to approximately $672,000 at June 30, 2020. The Company expects to recognize this revenue within the next three years.

4.	Inventory

Inventory consists of the following as of:

	June 30, 2020		December 31, 2019
Raw materials and work in process	$	1,761,658	$	1,495,190
Software licenses		210,000		332,500
Finished goods		1,627,322		1,412,528
Inventory, net, included in current assets		3,598,980		3,240,218
Software licenses – non-current		506,800		504,400
Total	$	4,105,780	$	3,744,618

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

5.	Notes Payable

2020 Secured Notes

On January 29, 2020 (the “Closing Date”), the Company completed a financing transaction (the “2020 Financing Transaction”) with two investors (the “2020 Convertible Noteholders”), whereby the Company issued an aggregate principal amount of $17,500,000 of the 2020 Secured Notes pursuant to a Securities Purchase Agreement (the “SPA”) dated January 11, 2020. Unless earlier converted or redeemed, the 2020 Secured Notes will mature on the fifth anniversary of the Closing Date, and bear interest at a rate equal to the sum of (i) the greater of (x) the three (3)-month London Interbank Offered Rate (“LIBOR”) and (y) two percent (2%), plus (ii) a margin of 2% on the outstanding balance of the 2020 Secured Notes, payable quarterly on the first business day of each calendar quarter. The 2020 Secured Notes may not be pre-paid without the consent of the noteholder, provided that the Company must offer to pre-pay such other noteholder on the same terms and conditions. Prior to maturity, the 2020 Convertible Noteholders will have the right to convert all or any portion of the outstanding balance of their notes, including any accrued but unpaid interest, into shares of the Company’s common stock at a conversion price of $6.00 per share, subject to certain adjustments as set forth in the 2020 Secured Notes. The 2020 Secured Notes are secured by all the assets of the Company.

Pursuant to the terms and subject to the conditions of the SPA, at any time on or prior to January 11, 2022, the Company shall have the right, but not the obligation, to request that one of the 2020 Convertible Noteholders purchase an additional $5,000,000 in aggregate principal amount of Second Closing Notes (as defined in the SPA) and an additional $10,000,000 in aggregate principal amount of additional Third Closing Notes (as defined in the SPA) (together, the “Additional Convertible Notes”), provided that such 2020 Convertible Noteholder has the right, but not the obligation, to purchase such notes. As of June 30, 2020, the Company had made no requests of the 2020 Convertible Noteholder to purchase any of the Additional Convertible Notes. The terms of the Additional Convertible Notes are the same as the terms of the 2020 Secured Notes, except that: (a) the Additional Convertible Notes would bear interest at a rate equal to the sum of (i) the greater of (x) the three (3)-month LIBOR and (y) 2%, plus (ii) a margin of 7% on their outstanding balance; and (b) only 70% of the Additional Convertible Notes’ principal amount outstanding would be convertible into shares of the Company’s common stock.

The carrying amount of the 2020 Secured Notes in the accompanying June 30, 2020 condensed consolidated balance sheet is presented net of: (a) financing costs, comprised of commissions and legal expenses, having an unamortized balance of $408,631; and (b) a discount, comprised of a commitment fee paid to one of the 2020 Convertible Noteholders, having an unamortized balance amounting to $277,270 at that date. The unamortized balance of the financing costs and the discount are charged to interest expense over the term of the 2020 Secured Notes under the effective interest method.

An executive officer of one of the 2020 Convertible Noteholders is a member of the Company’s Board of Directors, and, pursuant to the terms of the SPA and a Board Observer Agreement entered into by the other 2020 Convertible Noteholder and the Company, the other 2020 Convertible Noteholder appointed an individual to attend and observe meetings of the Company’s Board of Directors.

On January 27, 2020, as a condition to completion of the 2020 Financing Transaction, the Company entered into the Fourth Omnibus Amendment to the 2010 Secured Notes, whereby the 2010 Secured Notes were subordinated to the Company’s obligations under the terms of the 2020 Secured Notes and the Additional Convertible Notes, as applicable. During its first fiscal quarter of 2020, the Company repaid in full the aggregate outstanding principal amount of the 2010 Secured Notes, amounting to approximately $2.8 million, which, along with the Company’s payment of accrued interest amounting to approximately $920,000, resulted in the full retirement of the 2010 Secured Notes.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Payroll Protection Program Loan

In April 2020, the Company received $896,000 in proceeds through an unsecured loan funded under the Payroll Protection Program as part of the CARES Act, which was enacted by the U.S. Congress in response to the COVID-19 pandemic. The loan has a two-year term, bears an interest at rate of 1% per annum, and is payable monthly from November 2020 through the remainder of the note’s term in equal monthly installments of principal and interest amounting to $50,424.18. Management’s plan during the period in which the Company is affected by the COVID-19 pandemic is to retain its employee base and, pending the ultimate duration and impact of the COVID-19 pandemic and by using the funds for the purposes described under the terms of the loan, consider whether to repay the loan in conformity with its terms or request that all or a portion of the loan, as applicable under its terms, be ultimately forgiven. However, there is no assurance that the Company would be successful in obtaining such forgiveness.

2010 Secured Notes

The indebtedness outstanding under the 2010 Secured Notes at December 31, 2019 was $2.8 million. As discussed above, during the first fiscal quarter of 2020, the Company repaid in full the aggregate outstanding principal amount of the 2010 Secured Notes, together with accrued interest. The Company’s Chairman of its Board of Directors and one of the Company’s officers held 2010 Secured Notes purchased at the date of original issuance having an aggregate principal balance of $197,000.

The carrying amount of the 2010 Secured Notes in the accompanying December 31, 2019 condensed consolidated balance sheet is presented net of a discount, having an unamortized balance amounting to $765,073 at that date, arising from shares issued to the noteholders at issuance of the 2010 Secured Notes. During the six months ended June 30, 2020, the unamortized balance of this discount was charged to interest expense upon the Company’s repayment of the 2010 Secured Notes.

Scheduled Notes Payable Maturities

Scheduled principal payments as of June 30, 2020 with respect to notes payable are summarized as follows:

Years ending December 31,
2020	$	73,984
2021		446,504
2022		375,512
2023		—
2024		—
Thereafter		17,500,000
Total scheduled principal payments		18,396,000
Less: Unamortized financing costs and discount		(685,901	)
Total	$	17,710,099

6.	Leases

The Company leases office space in Irvine, California that houses its headquarters and manufacturing facility under a non-cancellable operating lease. The lease term commenced on October 1, 2018 and expires in September 2023. The Company has the option to renew the lease for two additional periods of five years each. The Company also leases office space in Mississauga, Ontario, Canada for its software development personnel. The lease term commenced on August 1, 2018, is set to expire in July 2021, and provides for automatic one-year renewals at the Company’s option. Both office leases are classified as operating leases in conformity with the provisions of Topic 842.

The lease costs included in general and administrative expenses were $28,219 and $28,617 for the three months ended June 30, 2020 and 2019, respectively, and were $56,438 and $55,620 for the six months ended June 30, 2020 and 2019, respectively.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

7.	Stockholders’ Equity

2019 Private Placement

On May 9, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Investors”) for the private placement of 2,426,455 shares of the Company’s common stock at $3.10 per share. The Company received aggregate gross proceeds of approximately $7.5 million, before deducting offering expenses aggregating approximately $94,000.

The Purchase Agreement also contains representations and warranties by the Company and the Investors and covenants of the Company and the Investors (including indemnification from the Company in the event of breaches of its representations and warranties), certain information rights and other rights, obligations and restrictions, which the Company believes are customary for transactions of this type.

Issuance of Common Stock in Lieu of Cash Payments

Under the terms of the Amended and Restated Non-Employee Director Compensation Plan, each compensated non-employee member of the Company’s Board of Directors may elect to receive all or part of his or her director fees in shares of the Company’s common stock. Director fees, whether paid in cash or in shares of common stock, are payable quarterly on the last day of each fiscal quarter. The number of shares of common stock issued to directors is determined by dividing the product of: (i)(a) the fees otherwise payable to each director in cash, times (b) the percentage of fees the director elected to receive in shares of common stock, by (ii) the volume weighted average price per share of common stock over the last five trading days of the quarter. The following is information regarding the number of shares issued to directors as payment for director fees in lieu of cash for the three and six months ended June 30, 2020 and 2019:

Three Months Ended June 30,
2020		2019
9,832		8,841

Six Months Ended June 30,
2020		2019
	19,563		17,739

Stock Incentive Plans

The Company has various share-based compensation plans and share-based compensatory contracts (collectively, the “Plans”) under which it has granted share-based awards, such as stock grants, and incentive and non-qualified stock options, to employees, directors, consultants and advisors. Awards may be subject to a vesting schedule as set forth in individual award agreements. Certain of the Plans also have provided for cash-based performance bonus awards.

From October 2017 until June 2020, the Company granted share-based awards under the Company’s Second Amended and Restated 2013 Incentive Compensation Plan (the “Second Amended Plan”). On June 2, 2020, the Company’s stockholders approved the Company’s Third Amended and Restated 2013 Incentive Compensation Plan (the “Third Amended Plan” and, together with the Second Amended Plan, the “2013 Plan”), under which 1 million shares of the Company’s common stock were made available for future issuances under the 2013 Plan, resulting in a total of 2,956,250 shares of the Company’s common stock being reserved for issuance under the 2013 Plan. Of this amount, stock grants of 440,995 shares have been awarded and option grants, net of options terminated, expired or forfeited, of 1,175,679 shares were outstanding as of June 30, 2020. Accordingly, 1,339,576 shares remained available for grants under the 2013 Plan as of that date.

ClearPoint Neuro, Inc.

(formerly MRI Interventions, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Stock option activity under all of the Company’s Plans during the six months ended June 30, 2020 is summarized below:

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾
Outstanding at January 1, 2020		1,639,167		$	9.87	$	2,892,027
Granted		84,445			4.14		26,512
Exercised		(833	)		1.74
Outstanding at June 30, 2020		1,722,779		$	9.59	$	867,568

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

As of June 30, 2020, there was unrecognized compensation expense of $948,807 related to outstanding stock options and shares of restricted stock, which is expected to be recognized over a weighted average period of 1.44 years.

Warrants

Warrants have generally been issued in connection with financing transactions and for terms of up to five years. Common stock warrant activity for the six months ended June 30, 2020 was as follows:

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾
Outstanding at January 1, 2020		5,532,267		$	4.00	$	10,470,008
Exercised		(428,532	)		2.20
Outstanding at June 30, 2020		5,103,735		$	4.15	$	2,717,201

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and the related notes thereto appearing in Part I, Item 1 of this Quarterly Report. This discussion and analysis contains forward-looking statements that are based upon current expectations and involve risks, assumptions and uncertainties. You should review the section titled “Risk Factors” appearing in our 2019 Form 10-K and in Part II, Item 1.A of this Quarterly Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis. In addition, historical results and trends that might appear in this Quarterly Report should not be interpreted as being indicative of future operations.

Overview

We are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain under direct, intra-procedural MRI guidance. Our principal product platform is our ClearPoint system, which is in commercial use and is used to perform minimally invasive surgical procedures in the brain. The ClearPoint system utilizes intra-procedural MRI to guide the procedures and is designed to work in a hospital’s existing MRI suite. We believe that this product platform delivers better patient outcomes, enhances revenue potential for both physicians and hospitals, and reduces costs to the healthcare system.

In 2010, we received regulatory clearance from the FDA to market our ClearPoint system in the U.S. for general neurological procedures. In addition, in 2011, we also obtained CE marking approval for our ClearPoint system, which enables us to sell our ClearPoint system in the European Union. The majority of our product revenues for the three and six months ended June 30, 2020 relate to sales of our ClearPoint system products. We have financed our operations and internal growth primarily through the sale of equity securities, the issuance of convertible and other secured notes, and license arrangements. We have incurred significant losses since our inception in 1998 as we have devoted substantial efforts to research and development. As of June 30, 2020, we had accumulated losses of approximately $116 million. We may continue to incur operating losses as we expand our ClearPoint system platform and our business generally.

Factors Which May Influence Future Results of Operations

The following is a description of factors that may influence our future results of operations, and that we believe are important to an understanding of our business and results of operations.

COVID-19

On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic, and on March 13, 2020, the President of the United States proclaimed that the COVID-19 outbreak in the United States constituted a national emergency. Continued widespread infection in the United States is a possibility. Extraordinary actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-19, including issuance of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations. These measures, while intended to protect human life, have led to reduced economic activity, including the postponement or cancellation of elective surgical procedures, which historically have represented approximately 80% of the number of surgical procedures using the Company’s ClearPoint system. In June 2020, the National Bureau of Economic Research officially declared that the United States economy has fallen into a recession. Although much of the United States economy is now in the process of reopening, the COVID-19 pandemic is intensifying in many areas of the country. The rapid development and fluidity of the situation precludes any prediction as to the ultimate impact COVID-19 will have on the Company’s business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-19 outbreak in the United States.

Key Performance Indicators

The key performance indicators we utilize on a tactical basis are integrated into our longer-term strategic plan within the following categories:

Functional neurosurgery navigation

Case volume – Underlying the revenue from sales of our functional neurosurgical products reflected in the accompanying Condensed Consolidated Financial Statements appearing elsewhere in this Quarter Report are the procedures, or cases, performed in hospitals utilizing one or more of our products or our clinical services. Case volume data is not influenced by variations in pricing or quantities of product used on a per case basis, and thus provide a more reliable indicator of the growth of our functional neurosurgery navigation line of business. Management analyzes case volume by hospital and by type of procedure to gain information that informs targeted sales and marketing activities. During the three and six months ended June 30, 2020, the ClearPoint system was used in 127 and 308 cases, respectively, as compared to 197 and 372 cases during the same respective periods in 2019, representing decreases of 36% for the comparative three-month periods and 17% for the comparative six-month periods. Consistent with the discussion in the section “Results of Operations –Revenues,” these increases were lower, relative to the quarterly year-over-year increases we experienced prior to the onset of the COVID-19 pandemic, which we attribute to the COVID-19 pandemic.

Number of “Active Surgical Centers” – For purposes of analyzing this performance indicator, an Active Surgical Center is a hospital that has purchased products from us or has performed procedures utilizing our ClearPoint system within a rolling 24-month period, and includes hospital sites having purchased the ClearPoint system, as well as sites in which the ClearPoint system is being used on an evaluation basis. The justification for including “evaluation sites” is that our disposable neurosurgical product is sold to such hospitals for their use in cases. In addition to signifying growth, the number of Active Surgical Centers, when analyzed in conjunction with case volume data, further informs targeted sales and marketing activities and confirms where these activities have led to increased penetration of our product lines. As of June 30, 2020, the ClearPoint system was used in more than 60 Active Surgical Centers, as compared to more than 50 such centers as of the same date in 2019.

Biologics and drug delivery

Number of “Partners” – Underlying the revenue from sales of products and services to our biologics and drug delivery customers is the number of customers, or “Partners.” Our Partners consist of pharmaceutical and biotech companies that are developing methods to deliver a wide variety of molecules, genes or proteins to targeted brain tissue or structures that would need to bypass the blood-brain barrier for the treatment of a variety of disorders. This is a novel area in which commercialization must be preceded by FDA-mandated clinical trials, which are expensive and time consuming to conduct, and for which the commercial success is uncertain, pending, in part, the outcome of those trials. While our revenues from sales of products and services to these Partners in support of their clinical trials are indicative of growth, the number of such relationships is also of importance as we recognize the possibility that some Partners’ research will reach commercial success, and others may not. To the extent our Partners achieve commercial success, our expectation is that we will share in such success through the use of our products and services in delivering our Partners’ therapies. At each of June 30, 2020 and 2019, we had commercial relationships with approximately 20 Partners, with acquisition activity in the biotechnology space during the year between these dates being substantially offset by new relationships we entered into over that same period.

Therapy products – We do not expect meaningful revenue from therapy products in 2020 and are targeting a limited market release of such products in 2021. As a result, our milestones in the therapy space are focused on refining the product and obtaining regulatory clearance. Should we be successful in achieving these milestones, we believe our initial performance indicators will focus on case volume and number of Active Surgical Centers, as are currently used in measuring our performance in functional neurosurgery navigation.

Global scale and efficiency – We have been cautious in setting our goals for operations beyond the U.S. so as to conserve our resources and not establish a foreign presence in advance of being assured of a corresponding revenue stream. In 2020 we expect to take the first steps in leveraging the CE Marks we have for our ClearPoint system and SmartFlow cannula to establish an initial presence in Europe for product sales and clinical advisory services. From this initial presence, we believe that future global key performance indicators will be similar to those described above for our U.S. business: case volume, number of Active Surgical Centers and number of biologics and drug delivery Partners.

Revenues

In 2010, we received 510(k) clearance from the FDA to market our ClearPoint system in the U.S. for general neurological procedures. Future revenues from sales of our ClearPoint platform products and services are difficult to predict and may not be sufficient to offset our continuing research and development expenses and our increasing selling, general and administrative expenses.

Generating recurring revenues from the sale of functional neurosurgical products is an important part of our business model for our ClearPoint system. We anticipate that, over time, recurring revenues will constitute an increasing percentage of our total revenues as we leverage installations of our ClearPoint system to generate recurring sales of our functional neurosurgical products. Our product revenues were approximately $1.6 million and $3.7 million for the three and six months ended June 30, 2020, respectively, and predominantly related to our ClearPoint system.

In addition, we expect that, over time, service revenues will constitute an increasing portion of our total revenues based on: (a) leveraging current and future installations of ClearPoint systems, as discussed above, so as to result in an increase in functional neurosurgical service revenues; and (b) increasing biologics and drug delivery service revenues should our customers in this space be successful in expansion of their clinical trials, and should we be successful in continuing to establish relationships with new biologic and drug delivery partners. Our service revenues were approximately $885,000 and $1.9 million for the three and six months ended June 30, 2020, respectively.

Our revenue recognition policies are more fully described in Note 2 to the Condensed Consolidated Financial Statements included above in Part I, Item 1 in this Quarterly Report.

Cost of Revenues

Cost of revenues includes the direct costs associated with the assembly and purchase of components for functional neurosurgical products, drug delivery and biologic products, non-neurosurgical therapy products, and ClearPoint capital equipment which we have sold, and for which we have recognized the revenue in accordance with our revenue recognition policy. Cost of revenues also includes the allocation of manufacturing overhead costs and depreciation of loaned systems installed under our ClearPoint placement program, as well as provisions for obsolete, impaired, or excess inventory. With the anticipated increases in the contribution to total revenues of sales of recurring products and services, as discussed above, we expect gross margin, as a percentage of total revenue, to increase over time.

Research and Development Costs

Our research and development costs consist primarily of costs associated with the conceptualization, design, testing, and prototyping of our ClearPoint system products. Such costs include salaries, travel, and benefits for research and development personnel, including related share-based compensation; materials and laboratory supplies in research and development activities; consultant costs; and licensing costs related to technology not yet commercialized. We anticipate that, over time, our research and development costs may increase as we: (i) continue to develop enhancements to our ClearPoint system; and (ii) seek to expand the application of our technological platforms. From our inception through June 30, 2020, we have incurred approximately $58 million in research and development expenses.

Product development timelines, likelihood of success, and total costs can vary widely by product candidate. There are also risks inherent in the regulatory clearance and approval process. At this time, we are unable to estimate with any certainty the costs that we will incur in our efforts to expand the application of our technological platforms.

Sales and Marketing, and General and Administrative Expenses

Our sales and marketing, and general and administrative expenses consist primarily of salaries, incentive-based compensation, travel and benefits, including related share-based compensation; marketing costs; professional fees, including fees for attorneys and outside accountants; occupancy costs; insurance; and other general and administrative expenses, which include, but are not limited to, corporate licenses, director fees, hiring costs, taxes, postage, office supplies and meeting costs. Our sales and marketing expenses are expected to increase due to costs associated with the commercialization of our ClearPoint system and the increased headcount necessary to support growth in operations.

Critical Accounting Policies

There have been no significant changes in our critical accounting policies during the three or six months ended June 30, 2020 as compared to the critical accounting policies described in our 2019 Form 10-K.

Results of Operations

Three Months Ended June 30, 2020 Compared to the Three Months Ended June 30, 2019

	Three Months Ended June 30,
	2020			2019			Percentage Change
Product revenues	$	1,593,070		$	2,194,194			(27%	)
Service and other revenues		884,712			412,204			115%
Total revenues		2,477,782			2,606,398			(5%	)
Cost of revenues		640,805			1,030,316			(38%	)
Research and development costs		822,301			697,803			18%
Sales and marketing expenses		1,124,378			1,143,056			(2%	)
General and administrative expenses		1,365,084			1,028,291			33%
Other income (expense):
Other income, net		10,851			1,693			541%
Interest expense, net		(197,113	)		(259,020	)		(24%	)
Net loss	$	(1,661,048	)	$	(1,550,395	)		7%

Revenues. Total revenues were $2.5 million for the three months ended June 30, 2020, and $2.6 million for the three months ended June 30, 2019, which represents a decrease of $129,000, or 5%.

Functional neurosurgery revenue, which consists of disposable product commercial sales related to cases utilizing the ClearPoint system, decreased 38% to $1.0 million for the three months ended June 30, 2020, from $1.7 million for the same period in 2019. This decrease was due to the effects of the COVID-19 pandemic, in which elective surgical procedures, historically representing approximately 80% of our ClearPoint system case volume, were postponed or cancelled. Although elective surgeries have been resumed, albeit at reduced levels, or the resumption is being considered, in certain areas of the U.S., we are unable to determine the extent to which such factors as the timing, adoption or viability of such resumption will impact our revenue. Accordingly, we are unable to determine the length of time that the COVID-19 pandemic will adversely affect our product revenues. There were no increases in functional neurosurgery product prices during the period between the three months ended June 30, 2020 and the same period in 2019 that would be reasonably expected to affect a typical customer order.

Biologics and drug delivery revenues, which include sales of disposable products and services related to customer-sponsored clinical trials utilizing the ClearPoint system, increased 183% to $1.2 million for the three months ended June 30, 2020, from $413,000 for the same period in 2019. This increase was due primarily to an increase, during the quarter ended June 30, 2020, relative to the same period in 2019, in biologic and drug delivery service revenues of $592,000. This increase in biologics and drug delivery service revenues is attributable to the establishment of additional relationships with biologic and drug delivery companies that included period-based retainers for clinical services in support of such companies’ respective clinical trials. Also contributing to the increase in biologics and drug delivery revenues was an increase of $162,000 in related product revenues that was also attributable to the establishment of additional relationships with biologic and drug delivery companies who ordered product for their clinical trials. These increases notwithstanding, our biologic and drug delivery customers are reestablishing their estimated timelines for initiation or resumption of their clinical trials, however, these timelines have not been finalized, given the uncertainties of when hospitals will be able to resume such clinical trial cases. Accordingly, depending on the length of the pandemic, future biologics and drug delivery revenues could be adversely impacted. In this context, however, it should be noted that the terms of our product sales do not provide the customer with a right of return for any reason other than for defective product or product that does not conform to a customer’s specifications. There were no increases in biologics and drug delivery product prices during the period between the three months ended June 30, 2020 and the same period in 2019 that would be reasonably expected to affect a typical customer order.

Capital equipment revenue, consisting of sales of ClearPoint reusable hardware and software, decreased 52% to $116,000 for the three months ended June 30, 2020, from $241,000 for the same period in 2019. While revenues from this product line historically have varied from quarter to quarter, we believe that many hospitals have postponed capital equipment acquisition activities, which continued postponement we believe will be contingent upon the prevalence and duration of the COVID-19 pandemic. There were no increases in capital equipment product prices during the period between the three months ended June 30, 2020 and the same period in 2019 that would be reasonably expected to affect a typical customer order.

Capital equipment-related services, consisting of fees for capital equipment rental, service, installation, training and shipping, decreased 49% to $124,000 for the three months ended June 30, 2020, from $244,000 for the same period in 2019. The decrease was due primarily to decreases in fees related to capital equipment sales, which were partially offset by an increase in equipment service contracts.

Cost of Revenues. Cost of revenues was $641,000, representing a gross margin of 74%, for the three months ended June 30, 2020, and was $1.0 million, representing a gross margin of 60%, for the three months ended June 30, 2019. This increase in gross margin was due primarily to a shift in the mix of revenues by line of business that resulted in service revenues, which bear higher gross margins in comparison to other product lines, representing a greater contribution to total sales for the three months ended June 30, 2020, relative to the same period in 2019. Also contributing to the improvement in gross margin was a lower allocation of overhead costs to sales for the three months ended June 30, 2020 as compared to the same period in 2019, resulting from the reduced sales volume during such 2020 period as compared to the same period in 2019, and a reduction in the allowance for excess and obsolete inventory. While we believe that these factors may prevail during the period that precautionary measures are in effect due to the COVID-19 pandemic, we also believe there is a possibility that gross margin may erode from its current level in the event that the mix of revenues and overhead allocations return to historical norms.

Research and Development Costs. Research and development costs were $822,000 for the three months ended June 30, 2020, compared to $698,000 for the same period in 2019, an increase of $124,000, or 18%. The increase was due primarily to increases in personnel costs of $84,000 due to increases in headcount and compensation, license amortization costs of $30,000 resulting primarily from licensing rights acquired in 2020, and outside consulting costs of $41,000 in connection with enhancements to the Company’s quality system.

Sales and Marketing Expenses. Sales and marketing expenses were $1.1 million for each of the three months ended June 30, 2020 and 2019. A decrease during the three months ended June 30, 2020 as compared to the same period in 2019 in travel and entertainment expenses of $137,000, resulting primarily from reduced activity due to the COVID-19 pandemic, was offset by an increase in personnel costs of $189,000, resulting primarily from headcount increases in our clinical and marketing teams, the effect of which was partially offset by a decrease in incentive compensation from reduced sales volume due to the COVID-19 pandemic.

General and Administrative Expenses. General and administrative expenses were $1.4 million for the three months ended June 30, 2020, compared to $1.0 million for the same period in 2019, an increase of $337,000, or 33%. This increase was due primarily to increases in share-based compensation of $37,000, professional fees of $106,000 and insurance costs of $20,000, and a $104,000 reduction of allocation of shared departmental resources to production due to the reduced manufacturing activity as an effect of the COVID-19 pandemic.

Interest Expense. Net interest expense for the three months ended June 30, 2020 was $197,000, compared with $259,000 for the same period in 2019. This decrease was primarily due to a $160,000 decrease in the amortization of the discount associated with the 2010 Secured Notes, which were repaid and retired during the fiscal quarter ended March 31, 2020, and to the repayment, in June 2019, of secured notes issued in 2014. This decrease was partially offset by a $111,000 increase in interest expense associated with the 2020 Secured Notes issued in January 2020. Additional information with respect to the 2010 Secured Notes and the 2020 Secured Notes is in Note 5 to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report.

Six Months Ended June 30, 2020 Compared to the Six Months Ended June 30, 2019

	Six Months Ended June 30,
	2020			2019			Percentage Change
Product revenues	$	3,696,455		$	4,358,148			(15%	)
Service and other revenues		1,896,921			720,767			163%
Total revenues		5,593,376			5,078,915			10%
Cost of revenues		1,558,141			1,916,798			(19%	)
Research and development costs		1,651,829			1,282,343			29%
Sales and marketing expenses		2,422,972			2,183,769			11%
General and administrative expenses		2,643,593			1,961,322			35%
Other income (expense):
Other income, net		6,131			7,322			(16%	)
Interest expense, net		(1,038,846	)		(513,125	)		102%
Net loss	$	(3,715,874	)	$	(2,771,120	)		34%

Revenues. Total revenues were $5.6 million for the six months ended June 30, 2020, and $5.1 million for the six months ended June 30 31, 2019, which represents an increase of $514,000, or 10%.

Functional neurosurgery revenue, which consists of disposable product commercial sales related to cases utilizing the ClearPoint system, decreased 17% to $2.7 million for the six months ended June 30, 2020, from $3.3 million for the same period in 2019. This decrease was due to the effects of the COVID-19 pandemic, in which elective surgical procedures, historically representing approximately 80% of our ClearPoint system case volume, were postponed or cancelled. Although elective surgeries have been resumed, or the resumption is being considered, in certain areas of the U.S., we are unable to determine the extent to which such factors as the timing, adoption or viability of such resumption will impact our revenue. Accordingly, we are unable to determine the length of time that the COVID-19 pandemic will adversely affect our product revenues. There were no increases in functional neurosurgery product prices during the period between the six months ended June 30, 2020 and the same period in 2019 that would be reasonably expected to affect a typical customer order.

Biologics and drug delivery revenues, which include sales of disposable products and services related to customer-sponsored clinical trials utilizing the ClearPoint system, increased 176% to $2.2 million for the six months ended June 30, 2020, from $795,000 for the same period in 2019. This increase was due primarily to an increase, during the six months ended June 30, 2020, relative to the same period in 2019, in biologic and drug delivery service revenues of $1.4 million. This increase in biologics and drug delivery service revenues is attributable to the establishment of additional relationships with biologic and drug delivery companies that included period-based retainers for clinical services in support of such companies’ respective clinical trials. This increase notwithstanding, our biologic and drug delivery customers are reestablishing their estimated timelines for initiation or resumption of their clinical trials, however, these timelines have not been finalized, given the uncertainties of when hospitals will be able to resume such clinical trial cases. Accordingly, depending on the length of the pandemic, future biologics and drug delivery revenues could be adversely impacted. In this context, however, it should be noted that the terms of our product sales do not provide the customer with a right of return for any reason other than for defective product or product that does not conform to a customer’s specifications. There were no increases in biologics and drug delivery product prices during the period between the six months ended June 30, 2020 and the same period in 2019 that would be reasonably expected to affect a typical customer order.

Capital equipment revenue, consisting of sales of ClearPoint reusable hardware and software, decreased 41% to $304,000 for the six months ended June 30, 2020, from $516,000 for the same period in 2019. While revenues from this product line historically have varied from quarter to quarter, we believe that many hospitals have postponed capital equipment acquisition activities, which postponement we believe to be contingent upon the prevalence and duration of the COVID-19 pandemic. There were no increases in capital equipment product prices during the period between the six months ended June 30, 2020 and the same period in 2019 that would be reasonably expected to affect a typical customer order.

Capital equipment-related services, consisting of fees for capital equipment rental, service, installation, training and shipping, decreased 38% to $280,000 for the six months ended June 30, 2020, from $455,000 for the same period in 2019. The decrease was due primarily to decreases in fees related to capital equipment sales, which were partially offset by an increase in equipment service contracts.

Cost of Revenues. Cost of revenues was $1.6 million, representing a gross margin of 72%, for the six months ended June 30, 2020, and was $1.9 million, representing a gross margin of 62%, for the six months ended June 30, 2019. This increase in gross margin was due primarily to a shift in the mix of revenues by line of business that resulted in service revenues, which bear higher gross margins in comparison to other product lines, representing a greater contribution to total sales for the six months ended June 30, 2020, relative to the same period in 2019. Also contributing to the improvement in gross margin was a lower allocation of overhead costs to sales for the six months ended June 30, 2020 as compared to the same period in 2019, resulting from the reduced sales volume during such 2020 period as compared to the same period in 2019, and a reduction in the allowance for excess and obsolete inventory. While we believe that these factors may prevail during the period that precautionary measures are in effect due to the COVID-19 pandemic, we also believe there is a possibility that gross margin may erode from its current level in the event that the mix of revenues and overhead allocations return to historical norms.

Research and Development Costs. Research and development costs were $1.7 million for the six months ended June 30, 2020, compared to $1.3 million for the same period in 2019, an increase of $369,000, or 29%. The increase was due primarily to increases in personnel costs of $171,000 due to increases in headcount and compensation, intellectual property costs of $109,000 due to increased project activity, license amortization costs of $59,000 resulting primarily from licensing rights acquired in 2020, and outside consulting costs of $84,000 in connection with enhancements to the Company’s quality system and pre-commercial license fees of $23,000 resulting from an increase in project activity. Partially offsetting these increases was a decrease in other product development costs of $63,000.

Sales and Marketing Expenses. Sales and marketing expenses were $2.4 million for the six months ended June 30, 2020 and $2.2 million for the same period in 2019. The increase was due primarily to increases in personnel costs of $428,000 resulting from headcount increase in our clinical and marketing teams, and meeting costs of $75,000. These increases were partially offset by decreases during the six months ended June 30, 2020 as compared to the same period in 2019 in travel and entertainment expenses of $173,000 and incentive compensation costs of $203,000, both decreases resulting from reduced activity due to the COVID-19 pandemic.

General and Administrative Expenses. General and administrative expenses were $2.6 million for the six months ended June 30, 2020, compared to $2.0 million for the same period in 2019, an increase of $682,000, or 35%. This increase was due primarily to increases in share-based compensation of $187,000, professional fees of $212,000, insurance costs of $37,000, and a $155,000 reduction of allocation of shared departmental resources to production due to the reduced manufacturing activity as an effect of the COVID-19 pandemic. These increases were partially offset by a $53,000 decrease in license expense.

Interest Expense. Net interest expense for the six months ended June 30, 2020 was $1.0 million, compared with $513,000 for the same period in 2019. This increase was primarily due to a $458,000 increase in the amortization of the discount associated with the 2010 Secured Notes, which were repaid and retired during the six months ended June 30, 2020, and interest expense associated with the issuance of the 2020 Secured Notes in January 2020. These increases were partially offset by interest incurred during the six months ended June 30, 2019 related to secured notes issued in 2014 and repaid in June 2019. Additional information with respect to the 2010 Secured Notes and the 2020 Secured Notes is in Note 5 to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report.

Liquidity and Capital Resources

We have incurred net losses since our inception which has resulted in a cumulative deficit at June 30, 2020 of $116 million. In addition, our use of cash from operations amounted to $4.0 for the six months ended June 30, 2020 and $2.8 million for the year ended December 31, 2019. Since inception, we have financed our operations principally from the sale of equity securities, the issuance of notes payable, product and service contracts and license arrangements.

As discussed in Note 7 to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report, in May 2019, we entered into the 2019 PIPE under which such investors purchased 2,426,455 shares of our common stock at $3.10 per share, resulting in proceeds of approximately $7.5 million, before deducting offering expenses aggregating approximately $94,000. In addition, as discussed in Note 5 to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report, in January 2020, we issued the 2020 Secured Notes, resulting in proceeds, net of financing costs paid and payable, and a commitment fee to one of the investors, of approximately $16.8 million. From the net proceeds received from the issuance of the 2020 Secured Notes, which have a five-year term, we repaid and retired the 2010 Secured Notes that otherwise would have matured in October and November 2020. Also, as discussed in Note 5 to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report, in April 2020 we received $896,000 in proceeds through a loan funded under the Payroll Protection Program as part of the CARES Act. Management’s plan during the period in which we are affected by the COVID-19 pandemic is to retain our employee base and, pending the ultimate duration and impact of the COVID-19 pandemic and by using the funds for the purposes described under the terms of the loan, consider whether to repay the loan in conformity with its terms or request that all or a portion of the loan, as applicable under its terms, be ultimately forgiven. However, there is no assurance that we would be successful in obtaining such forgiveness. Based on the foregoing, in management’s opinion, cash and cash equivalent balances at June 30, 2020, when combined with the proceeds from issuance of the 2020 Secured Notes (after repayment of the 2010 Secured Notes) and receipt of the proceeds from the loan funded under the Payroll Protection Program, are sufficient to support our operations and meet our obligations for at least the next twelve months.

Cash Flows

Cash activity for the six months ended June 30, 2020 and 2019 is summarized as follows:

	Six Months Ended June 30,
	2020			2019
Cash used in operating activities	$	(4,038,514	)	$	(1,419,570	)
Cash used in investing activities		(441,341	)		(150,000	)
Cash provided by financing activities		14,816,215			5,930,085
Net change in cash and cash equivalents	$	10,336,360		$	4,360,515

Net Cash Flows from Operating Activities. We used $4.0 million and $1.4 million of cash for operating activities during the six months ended June 30, 2020 and 2019, respectively.

During the six months ended June 30, 2020, uses of cash in operating activities primarily consisted of: (i) our $3.7 million net loss; (ii) increases in accounts receivable of $74,000, inventory of $313,000, and prepaid expenses and other current assets of $181,000; and (iii) decreases in accrued interest of $960,000, lease liabilities of $48,000, and deferred revenue of $366,000. These uses were partially offset by: (a) a decrease in other assets of $70,000; (b) an increase in accounts payable and accrued expenses of $93,000; and (c) net non-cash expenses included in our net loss aggregating $1.5 million and consisting primarily of depreciation and amortization, share-based compensation, and amortization of debt issuance costs, original issue discounts on debt and lease rights-of-use, net of accretion in lease liabilities.

During the six months ended June 30, 2019, uses of cash in operating activities primarily consisted of: (i) our $2.8 million net loss; (ii) increases in accounts receivable of $138,000, inventory of $202,000, and prepaid expenses and other current assets of $217,000; and (iii) a decrease in lease liabilities of $50,000. These uses were partially offset by: (a) a decrease in other assets of $12,000; (b) increases in accounts payable and accrued expenses of $716,000 and in deferred revenue of $389,000; and (c) net non-cash expenses included in our net loss aggregating $841,000 and consisting primarily of depreciation and amortization, share-based compensation, and amortization of debt issuance costs, original issue discounts on debt and lease rights-of-use, net of accretion in lease liabilities.

Net Cash Flows from Investing Activities. Net cash flows used in investing activities for the six months ended June 30, 2020 and 2019 were $441,000 and $150,000, respectively, and consisted of acquisitions of medical device license rights.

Net Cash Flows from Financing Activities. Net cash flows from financing activities for the six months ended June 30, 2020 consisted of the proceeds, net financing costs and discount paid as of that date, of $16.8 million received from the issuance of the 2020 Secured Notes, and the proceeds of $896,000 from the Payroll Protection Program loan. The proceeds from these activities were partially offset by the repayment of the 2010 Secured Notes amounting to $2.8 million. The 2020 Secured Notes, the Payroll Protection Act Loan and the repayment of the 2010 Secured Notes are described in Note 5 to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report.

Net cash flows from financing activities for the six months ended June 30, 2019 consisted of proceeds from cash proceeds of: (a) $7.5 million received from the sale of shares of our common stock under the terms of the 2019 PIPE as described in Note 7 to the condensed consolidated financial statements included elsewhere in this Quarterly Report; and (b) $383,000 received from warrant exercises. These proceeds were partially offset by the $2.0 million repayment, in June 2019, of secured notes that otherwise would have been due in September 2019.

Operating Capital and Capital Expenditure Requirements

To date, we have not achieved profitability. We could continue to incur net losses as we continue our efforts to expand the commercialization of our ClearPoint system products and pursue additional applications for our technology platforms. Our cash balances are primarily held in a variety of demand accounts with a view to liquidity and capital preservation.

Because of the numerous risks and uncertainties associated with the development and commercialization of medical devices, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to successfully commercialize our ClearPoint system products and pursue additional applications for our technology platforms. Our future capital requirements will depend on many factors, including, but not limited to, the following:

●

the ultimate duration and impact of the COVID-19 pandemic;

●

the timing of broader market acceptance and adoption of our ClearPoint system products;

●

the scope, rate of progress and cost of our ongoing product development activities relating to our ClearPoint system;

●

the cost and timing of expanding our sales, clinical support, marketing and distribution capabilities, and other corporate infrastructure;

●

the cost and timing of establishing inventories at levels sufficient to support our sales;

●

the effect of competing technological and market developments;

●

the cost of pursuing additional applications of our technology platforms under current collaborative arrangements, and the terms and timing of any future collaborative, licensing or other arrangements that we may establish;

●

the cost and timing of any clinical trials;

●

the cost and timing of regulatory filings, clearances and approvals; and

●

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

Off-Balance Sheet Arrangements

We are not a party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Interest Rate Risk

Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, because all our investments are in short-term bank deposits and institutional money market funds. The primary objective of our investment activities is to preserve principal while at the same time maximizing income we receive without significantly increasing risk. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure.

Foreign Currency Risk

To date, we have not recorded a significant amount of sales in currencies other than U.S. dollars, and have only limited business transactions in foreign currencies. We do not currently engage in hedging or similar transactions to reduce our foreign currency risks, which at present, are not material. We believe we have no material exposure to risk from changes in foreign currency exchange rates at this time. We will continue to monitor and evaluate our internal processes relating to foreign currency exchange, including the potential use of hedging strategies.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that material information relating to us is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2020 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2020.

Changes in Internal Control Over Financial Reporting

During the quarter ended June 30, 2020, there were no changes in our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Except as noted below, there have been no material changes to the risk factors disclosed in our 2019 Form 19-K under Item 1A. “Risk Factors.”

The COVID-19 pandemic and mitigation efforts to control the spread of the disease have and are expected to continue to materially impact our business, and our financial condition, results of operations and cash flows could be materially adversely affected by factors relating to COVID-19.

On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic, and on March 13, 2020, the President of the United States proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency. Continued widespread infection in the United States is a possibility. Extraordinary actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-19, including issuance of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations. These measures, while intended to protect human life, have led to reduced economic activity, including the postponement or cancellation of elective surgical procedures, which historically represents approximately 80% of the procedures utilizing our products and services. Furthermore, the business shutdowns and the disruptions to financial markets caused by COVID-19 pandemic has led to recessionary conditions in the economy in the short term, which could negatively impact our business, as hospitals curtail and reduce capital and overall spending.

The ongoing COVID-19 pandemic and restrictions intended to prevent its spread could have significant adverse impacts on our business, financial condition, results of operations and cash flows in a variety of ways that are difficult to predict. Such adverse impacts will depend on, among other factors:

federal, state, local and industry-initiated efforts that may adversely affect the ability to perform elective surgeries;

disruptions to the supply chain of critical components;

severe and prolonged disruption and instability in the financial markets, including the debt and equity capital markets, which have already experienced and may continue to experience significant volatility, or deteriorations in credit and financing conditions, which may affect our ability to access capital necessary to fund our business operations or refinance maturing debt on a timely basis, on attractive terms or at all, which would adversely affect our ability to meet liquidity and capital expenditure requirements;

sustained stock market volatility that negatively affects the market price of our securities, including market conditions unrelated to our operating performance or prospects;

our ability to manage our business to the extent our management or personnel are impacted in significant numbers by the COVID-19 pandemic and are not willing, available or allowed to conduct work; and

our ability to ensure business continuity in the event our continuity of operations plan is not effective or improperly implemented during the COVID-19 pandemic.

The ongoing COVID-19 pandemic and the current economic, financial and capital markets environment present material risks and uncertainties for us. However, the rapid development and fluidity of the situation precludes any prediction as to the ultimate impact COVID-19 will have on our business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-19 outbreak in the United States. To the extent the COVID-19 pandemic adversely affects our business, financial condition, results of operation and cash flows, it may also have the effect of heightening many of the other risks described in the “Risk Factors” section of our 2019 Form 10-K.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.

MINE SAFETY DISCLOSURES.

None.

ITEM 5.

OTHER INFORMATION.

None.

ITEM 6.

EXHIBITS.

The exhibits listed below are filed, furnished or incorporated by reference as part of this Quarterly Report.

Exhibit Number		Exhibit Description
10.1		ClearPoint Neuro, Inc. Third Amended and Restated 2013 Incentive Compensation Plan (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-34822) filed with the SEC on April 20, 2020)
31.1*		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934
31.2*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934
32+		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code
101.INS*		XBRL Instance
101.SCH*		XBRL Taxonomy Extension Schema
101.CAL*		XBRL Taxonomy Extension Calculation
101.DEF*		XBRL Taxonomy Extension Definition
101.LAB*		XBRL Taxonomy Extension Labels
101.PRE*		XBRL Taxonomy Extension Presentation

Filed herewith.

This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 13, 2020


	CLEARPOINT NEURO, INC.

	By:	/s/ Joseph M. Burnett
		Joseph M. Burnett
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Harold A. Hurwitz
		Harold A. Hurwitz
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934

I, Joseph M. Burnett, certify that:

I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2020, of ClearPoint Neuro, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 13, 2020	/s/ Joseph M. Burnett
	Joseph M. Burnett
	Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934

I, Harold A. Hurwitz, certify that:

I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2020, of ClearPoint Neuro, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 13, 2020	/s/ Harold A. Hurwitz
	Harold A. Hurwitz
	Chief Financial Officer

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) UNDER
THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 1350 OF
CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, Joseph M. Burnett and Harold A. Hurwitz, certifies pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this quarterly report on Form 10-Q for the quarter ended June 30, 2020, of ClearPoint Neuro, Inc. (the “Company”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, and (2) the information contained in this quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2020


	/s/ Joseph M. Burnett
	Joseph M. Burnett
	Chief Executive Officer

	/s/ Harold A. Hurwitz
	Harold A. Hurwitz
	Chief Financial Officer

EX-101.INS 5 clpt-20200630.xml XBRL INSTANCE FILE 0001285550 2020-08-10 0001285550 2019-06-30 0001285550 clpt:JuniorSecuredNotesPayable2014Member 2019-12-31 0001285550 clpt:SecuredNotesPayable2010Member 2020-06-30 0001285550 2018-12-31 0001285550 clpt:CapitalEquipmentRelatedServiceRevenueMember 2020-04-01 2020-06-30 0001285550 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001285550 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-06-30 0001285550 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001285550 srt:MaximumMember 2020-01-01 2020-06-30 0001285550 srt:MinimumMember 2020-01-01 2020-06-30 0001285550 us-gaap:JuniorSubordinatedDebtMember clpt:ChairmanAndOfficerMember 2019-12-31 0001285550 us-gaap:JuniorSubordinatedDebtMember 2019-12-31 0001285550 clpt:AmendedAndRestated2013IncentiveCompensationPlanMember 2020-06-30 0001285550 clpt:AmendedAndRestated2013IncentiveCompensationPlanMember 2020-01-01 2020-06-30 0001285550 2019-01-01 2019-12-31 0001285550 2019-12-31 0001285550 clpt:SecurityPurchaseAgreement2019Member clpt:AccreditedInvestorsMember 2019-01-01 2019-12-31 0001285550 clpt:SecurityPurchaseAgreement2019Member clpt:AccreditedInvestorsMember 2019-12-31 0001285550 clpt:SecurityPurchaseAgreementMember clpt:SecuredNotes2020Member 2020-01-01 2020-06-30 0001285550 clpt:SecurityPurchaseAgreementMember clpt:SecuredNotes2020Member 2020-06-30 0001285550 clpt:Product_FunctionalNeurosurgeryMember 2019-01-01 2019-06-30 0001285550 clpt:Product_FunctionalNeurosurgeryMember 2020-01-01 2020-06-30 0001285550 clpt:Product_BiologicsAndDrugDeliveryMember 2019-01-01 2019-06-30 0001285550 clpt:Product_BiologicsAndDrugDeliveryMember 2020-01-01 2020-06-30 0001285550 clpt:Product_CapitalEquipmentMember 2019-01-01 2019-06-30 0001285550 clpt:Product_CapitalEquipmentMember 2020-01-01 2020-06-30 0001285550 clpt:Services_BiologicsAndDrugDeliveryMember 2019-01-01 2019-06-30 0001285550 clpt:Services_BiologicsAndDrugDeliveryMember 2020-01-01 2020-06-30 0001285550 clpt:Services_CapitalEquipmentAndOtherMember 2019-01-01 2019-06-30 0001285550 clpt:Services_CapitalEquipmentAndOtherMember 2020-01-01 2020-06-30 0001285550 clpt:Products_TherapyMember 2019-01-01 2019-06-30 0001285550 clpt:Products_TherapyMember 2020-01-01 2020-06-30 0001285550 clpt:RemainingPerformanceObligationsCapitalEquipmentRelatedServiceRevenueMember 2020-01-01 2020-06-30 0001285550 clpt:CapitalEquipmentRelatedServiceRevenueMember 2020-01-01 2020-06-30 0001285550 clpt:DevelopmentServicesAgreementMember 2019-12-31 0001285550 clpt:LetterOfIntentMember us-gaap:InvestorMember 2019-12-31 0001285550 clpt:OfficeLeaseIrvineCaliforniaMember 2020-01-01 2020-06-30 0001285550 clpt:OfficeLeaseIrvineCaliforniaMember 2020-06-30 0001285550 clpt:OfficeLeaseMississaugaOntarioCanadaMember 2020-01-01 2020-06-30 0001285550 clpt:OfficeLeaseMississaugaOntarioCanadaMember 2020-06-30 0001285550 2020-01-01 2020-03-31 0001285550 2019-01-01 2019-03-31 0001285550 2019-03-31 0001285550 clpt:SbaPppMember 2020-01-01 2020-06-30 0001285550 clpt:SbaPppMember 2020-06-30 0001285550 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001285550 us-gaap:LicenseAgreementTermsMember 2020-01-01 2020-06-30 0001285550 us-gaap:LicenseAgreementTermsMember 2020-06-30 0001285550 clpt:DevelopmentServicesAgreementMember 2020-06-30 0001285550 clpt:LetterOfIntentMember us-gaap:InvestorMember us-gaap:UnbilledRevenuesMember 2019-12-31 0001285550 clpt:LetterOfIntentMember us-gaap:InvestorMember 2020-01-01 2020-06-30 0001285550 clpt:LetterOfIntentMember us-gaap:InvestorMember 2020-06-30 0001285550 us-gaap:JuniorSubordinatedDebtMember 2020-01-01 2020-06-30 0001285550 srt:DirectorMember 2020-01-01 2020-06-30 0001285550 srt:DirectorMember 2019-01-01 2019-06-30 0001285550 clpt:SecurityPurchaseAgreementMember clpt:ConvertibleNoteholders2020Member 2020-01-01 2020-06-30 0001285550 clpt:SecurityPurchaseAgreementMember clpt:ConvertibleNoteholders2020Member 2020-06-30 0001285550 2020-01-01 2020-06-30 0001285550 2020-04-01 2020-06-30 0001285550 2019-04-01 2019-06-30 0001285550 2019-01-01 2019-06-30 0001285550 us-gaap:ProductMember 2020-04-01 2020-06-30 0001285550 us-gaap:ProductMember 2019-04-01 2019-06-30 0001285550 us-gaap:ProductMember 2020-01-01 2020-06-30 0001285550 us-gaap:ProductMember 2019-01-01 2019-06-30 0001285550 us-gaap:ServiceMember 2020-04-01 2020-06-30 0001285550 us-gaap:ServiceMember 2019-04-01 2019-06-30 0001285550 us-gaap:ServiceMember 2020-01-01 2020-06-30 0001285550 us-gaap:ServiceMember 2019-01-01 2019-06-30 0001285550 2020-06-30 0001285550 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001285550 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001285550 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001285550 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001285550 us-gaap:CommonStockMember 2019-12-31 0001285550 us-gaap:CommonStockMember 2020-03-31 0001285550 us-gaap:CommonStockMember 2020-06-30 0001285550 us-gaap:CommonStockMember 2018-12-31 0001285550 us-gaap:CommonStockMember 2019-03-31 0001285550 us-gaap:CommonStockMember 2019-06-30 0001285550 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001285550 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001285550 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001285550 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001285550 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001285550 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001285550 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001285550 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001285550 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001285550 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001285550 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001285550 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001285550 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001285550 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001285550 us-gaap:RetainedEarningsMember 2019-12-31 0001285550 us-gaap:RetainedEarningsMember 2020-03-31 0001285550 us-gaap:RetainedEarningsMember 2020-06-30 0001285550 us-gaap:RetainedEarningsMember 2018-12-31 0001285550 us-gaap:RetainedEarningsMember 2019-03-31 0001285550 us-gaap:RetainedEarningsMember 2019-06-30 0001285550 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001285550 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-04-01 2019-06-30 0001285550 clpt:Product_FunctionalNeurosurgeryMember 2020-04-01 2020-06-30 0001285550 clpt:Product_FunctionalNeurosurgeryMember 2019-04-01 2019-06-30 0001285550 clpt:Product_BiologicsAndDrugDeliveryMember 2020-04-01 2020-06-30 0001285550 clpt:Product_BiologicsAndDrugDeliveryMember 2019-04-01 2019-06-30 0001285550 clpt:Products_TherapyMember 2020-04-01 2020-06-30 0001285550 clpt:Products_TherapyMember 2019-04-01 2019-06-30 0001285550 clpt:Product_CapitalEquipmentMember 2020-04-01 2020-06-30 0001285550 clpt:Product_CapitalEquipmentMember 2019-04-01 2019-06-30 0001285550 clpt:Services_CapitalEquipmentAndOtherMember 2020-04-01 2020-06-30 0001285550 clpt:Services_CapitalEquipmentAndOtherMember 2019-04-01 2019-06-30 0001285550 clpt:Services_BiologicsAndDrugDeliveryMember 2020-04-01 2020-06-30 0001285550 clpt:Services_BiologicsAndDrugDeliveryMember 2019-04-01 2019-06-30 0001285550 clpt:LetterOfIntentMember us-gaap:InvestorMember 2020-04-01 2020-06-30 0001285550 srt:DirectorMember 2020-04-01 2020-06-30 0001285550 srt:DirectorMember 2019-04-01 2019-06-30 0001285550 clpt:ThirdAmendedAndRestated2013IncentiveCompensationPlanMember 2020-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure clpt:Integer

2072583

16814099

17500000

0.01

25000000

0.01

200000000

15235308

15512687

15235308

15512687

89000

3294767

2733424

529859

580330

515692

303901

265611

1616428

455156

280493

17830

78800

672000

210000

5593376

2477782

2606398

5078915

1593070

2194194

3696455

4358148

884712

412204

1896921

720767

1049015

1690122

406955

244949

21300

17830

115800

241293

123998

243954

760714

168250

-2054825

-1220725

-3715873

-1661048

-1550395

-2771120

-2054825

-1661048

-1220725

-1550395

0.12

0.21

0.22

P3Y P1Y

29000

32000

1175679

1639167

1722779

440995

84445

2956250

1000000

1339576

19563

17739

9832

8841

A range of 30-60 days after the customers' receipt of the Company's invoices.

3832947

3823598

1016892

620126

113520

110914

328460

334627

1408292

969877

965783

1491377

11926437

23032849

82573

12438

504400

506800

447162

342584

10383084

21332665

357227

537940

3240218

3598980

1089917

1163663

374218

321155

197862

228286

276669

227714

959659

11926437

23032849

-112739620

-116455493

117173984

117640195

152353

155127

7339720

21693020

94000

94162

2426455

3.10

7500000

P5Y

7900000

127600

102000

625000

83000

429000

500000 250000

172000

143000

1495190

1761658

332500 210000

1412528

1627322

3744618 4105780 2018-10-01 2018-08-01

2023-09-30

2021-07-31

P5Y

P1Y

P5Y

P1Y

Bears interest at a rate equal to the sum of (i) the greater of (x) the three (3)-month London Interbank Offered Rate and (y) two percent (2%), plus (ii) a margin of 2% on the outstanding balance of the 2020 Notes, payable quarterly on the first business day of each calendar quarter.

6.00

At any time on or prior to January 11, 2022, the Company shall have the right, but not the obligation, to request that one of the 2020 Convertible Noteholders purchase an additional $5,000,000 in aggregate principal amount of Second Closing Notes (as defined in the SPA) and an additional $10,000,000 in aggregate principal amount of additional Third Closing Notes (as defined in the SPA) (together, the “Additional Convertible Notes”), provided that the such 2020 Convertible Noteholder has the right, but not the obligation, to purchase such notes. The terms of the Additional Convertible Notes are the same as the terms of the 2020 Secured Notes, except that: (a) the Additional Convertible Notes would bear interest at a rate equal to the sum of (i) the greater of (x) the three (3)-month London Interbank Offered Rate and (y) 2%, plus (ii) a margin of 7% on their outstanding balance; and (b) only 70% of the Additional Convertible Notes’ principal amount outstanding would be convertible into shares of the Company’s common stock.

920000 15731352

135000

517207

-2849515

-4038514

-1419570

16800000

591341

P5Y

500000

17500000

18396000

765073

408631

277270

685901

17710099

73984

446504

375512

2800000

896000

0.01

Payable monthly from November 2020 through the remainder of the note’s term in equal monthly installments of principal and interest amounting to $50,424.18.

P2Y

ClearPoint Neuro, Inc. 0001285550 10-Q 001-34822 2020-06-30 false --12-31 Yes true false Non-accelerated Filer false Q2 2020

15471222

15504169

12302667

11676872

-0.24

-0.11

-0.13

-0.24

1038846

197113

259020

513125

6131

10851

1693

7322

-2683158

-1474786

-1293068

-2265317

2643592

1365084

1028291

1961322

2422972

1124378

1143056

2183769

1651829

822301

697803

1282343

1558141

640805

1030316

1916798

6907142

1511002

4586717

442619

1339829

152353

155071

155127

110183

110672

136863

117173984

117399234

117640195

108600405

108752502

116741229

-112739620

-114794445

-116455493

-107199586

-108420555

-109970950

15235308

15507149

15512687

11018364

11067207

13686320

-244 -244 -244 -244

227968

152586

241017

203994

285

227871

240961

152301

203962

9696 5538 28462 3251 383076 2621 204 1894 -2621 -204 381182 262145 20381 189407

7461648

3101133

5695722

16032082

296677

599323

-366341 389201 -48280 -50285

93347

716222

-70134

-11899

180712

216953

49782

51255

821301

363465

468985

356580

116026

69600

-441341

-150000

441341 150000

14816215

5930085

2837656

1975000

383075

7522010

16757871

1043371

164157

47686 7427848 24265 7403583 2426455 <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 24px; font-family: Times New Roman,serif">1.</td> <td style="font-family: Times New Roman,serif; text-align: justify">Description of the Business and Financial Condition</td></tr> </table>   ClearPoint Neuro, Inc. (the “Company”) is a medical device company focused on the development and commercialization of technology that enables physicians to see inside the brain and heart using direct, intra-procedural magnetic resonance imaging (“MRI”) guidance while performing minimally invasive surgical procedures.   The Company’s ClearPoint® system, an integrated system comprised of capital equipment and disposable products, is designed to allow minimally invasive procedures in the brain to be performed in an MRI suite. The Company received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) in 2010 to market the ClearPoint system in the United States for general neurological interventional procedures. The Company’s ClearTrace® system is a product candidate that is designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. Although still a product candidate, the Company has reduced its efforts to commercialize the ClearTrace system.   On February 12, 2020, the Company changed its corporate name from MRI Interventions, Inc. to ClearPoint Neuro, Inc., pursuant to a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware. In addition, effective as of February 12, 2020, the Company’s Board of Directors adopted the Second and Amended Restated Bylaws, to reflect the name change of the Company. No other changes were made to the Company’s certificate of incorporation or bylaws. In connection with the Company’s name change, effective as of the opening of trading on February 12, 2020, the Company’s shares of common stock commenced trading on the Nasdaq Capital Market under the symbol “CLPT.”   COVID-19   On March 11, 2020, the World Health Organization characterized the spread of a novel strain of coronavirus (“COVID-19”) as a global pandemic, and on March 13, 2020, the President of the United States proclaimed that the COVID-19 outbreak in the United States constituted a national emergency. Continued widespread infection in the United States is a possibility. Extraordinary actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-19, including issuance of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations.  These measures, while intended to protect human life, have led to reduced economic activity, including the postponement or cancellation of elective surgical procedures, which historically have represented approximately 80% of the number of surgical procedures using the Company’s ClearPoint system. Furthermore, the recessionary conditions on the financial markets and global economy caused by the COVID-19 pandemic could have a material adverse effect on the Company’s business, as hospitals postpone or reduce capital purchases and overall spending. The rapid development and fluidity of the situation precludes any prediction as to the ultimate impact COVID-19 will have on the Company’s business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-19 outbreak in the United States.   Liquidity   The Company has incurred net losses since its inception, which has resulted in a cumulative deficit at June 30, 2020 of $116 million. In addition, the Company’s use of cash from operations amounted to $4.0 million for the six months ended June 30, 2020 and $2.8 million for the year ended December 31, 2019. Since its inception, the Company has financed its operations principally from the sale of equity securities, the issuance of notes payable, product and service contracts and license arrangements.   As discussed in Note 7, in May 2019, the Company entered into a Securities Purchase Agreement with certain accredited investors under which such investors purchased 2,426,455 shares of the Company’s common stock at $3.10 per share (the “2019 PIPE), resulting in proceeds of approximately $7.5 million, before deducting offering expenses aggregating approximately $94,000.   In addition, as discussed in Note 5, in January 2020, the Company entered into a Securities Purchase Agreement with two investors under which the Company issued to such investors an aggregate principal amount of $17.5 million of floating rate secured convertible notes (the “2020 Secured Notes”), resulting in proceeds, net of financing costs paid and payable, and a commitment fee paid to one of the investors, of approximately $16.8 million. From the net proceeds received from the issuance of the 2020 Secured Notes, which have a five-year term, the Company repaid and retired the 2010 Junior Secured Notes Payable (the “2010 Secured Notes”) that otherwise would have matured in October and November 2020.   Also, as discussed in Note 5, in April 2020, the Company received $896,000 in proceeds through a loan funded under the Payroll Protection Program as part of the CARES Act. Management’s plan during the period in which the Company is affected by the COVID-19 pandemic is to retain the Company’s employee base and, pending the ultimate duration and impact of the COVID-19 pandemic and by using the funds for the purposes described under the terms of the loan, consider whether to repay the loan in conformity with its terms or request that all or a portion of the loan, as applicable under its terms, be ultimately forgiven. However, there is no assurance that the Company would be successful in obtaining such forgiveness.   Based on the foregoing, in management’s opinion, cash and cash equivalent balances at June 30, 2020, when combined with the proceeds from issuance of the 2020 Secured Notes (after repayment of the 2010 Secured Notes) and receipt of the proceeds from the loan funded under the Payroll Protection Program, are sufficient to support the Company’s operations and meet its obligations for at least the next twelve months.

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 24px; font-family: Times New Roman,serif">2.</td> <td style="font-family: Times New Roman,serif; text-align: justify">Basis of Presentation and Summary of Significant Accounting Policies</td></tr> </table>   Basis of Presentation and Use of Estimates   In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2019 audited consolidated financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with United States Securities and Exchange Commission (“SEC”) rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2019 Form 10-K. The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for a complete set of financial statements. The results of operations for the three and six months ended June 30, 2020 may not be indicative of the results to be expected for the entire year or any future periods.   Inventory   Inventory is carried at the lower of cost (first-in, first-out method) or net realizable value. Items in inventory relate predominantly to the Company’s ClearPoint system. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for obsolete items and provides a reserve upon identification of potential obsolete items.   Intangible Assets   In June 2019 and February 2020, the Company entered into license agreements that provide rights to the Company for the development and commercialization of products in the functional neurosurgery field. Under the terms of those certain license agreements, the Company paid an aggregate $591,341 to the licensors upon execution of the license agreements for access to the underlying technologies and will make future payments based on the achievement of regulatory and commercialization milestones as defined in the license agreements.   In conformity with Accounting Standards Codification Section 350, “Intangibles – Goodwill and Other,” the Company amortizes its investment in the license rights described above over an expected useful life of five years.   Revenue Recognition   The Company’s revenues are comprised primarily of: (1) product revenues resulting from the sale of functional neurosurgical products, and drug delivery and biologic products; (2) product revenues resulting from the sale of ClearPoint capital equipment; (3) revenues resulting from the rental, service, installation, training and shipping related to ClearPoint capital equipment; and (4) clinical case support revenues in connection with customer-sponsored clinical trials. The Company recognizes revenue when control of the Company’s products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control.   Lines of Business; Timing of Revenue Recognition   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">Functional neurosurgery product, biologics and drug delivery systems product, and therapy product sales: Revenues from the sale of functional neurosurgery products (consisting of disposable products sold commercially and related to cases utilizing the Company’s ClearPoint system), biologics and drug delivery systems (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in non-neurosurgical procedures), are generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and are recognized at the point in time of delivery to the customer, which is the point at which legal title, and risks and rewards of ownership, along with physical possession, transfer to the customer.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Capital equipment sales</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Capital equipment sales preceded by evaluation periods: The predominance of capital equipment sales (consisting of integrated computer hardware and software that are integral components of the Company’s ClearPoint system) are preceded by customer evaluation periods of generally 90 days. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment sales following such evaluation periods is recognized at the point in time the Company is in receipt of an executed purchase agreement or purchase order.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Capital equipment sales not preceded by evaluation periods: Revenue from sales of capital equipment not having been preceded by an evaluation period is recognized at the point in time that the equipment has been delivered to the customer.</td></tr></table>   For both types of capital equipment sales described above, the Company’s determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Functional neurosurgery and related services: Revenues from functional neurosurgery and related services are recognized over the period of time such services are rendered.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Biologics and drug delivery services:</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Outsourced technical clinical support of cases performed pursuant to customer-sponsored clinical trials:</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in">§</td><td style="text-align: justify">Service Access Fees: For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by Company personnel during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in">§</td><td style="text-align: justify">Procedure-Based Fees: The Company recognizes revenue at the point in time a case is attended by Company personnel.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Therapy services: The Company recognizes revenue for such services at the point in time that the performance obligation has been satisfied.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Capital equipment-related services:</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Equipment service: Revenue from service of ClearPoint capital equipment previously sold to customers is based on agreements with terms ranging from one to three years and revenue is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for rental and service revenues because the Company transfers control evenly by providing a stand-ready service.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Installation, training and shipping: Consistent with the Company’s recognition of revenue for capital equipment sales as described above, fees for installation, training and shipping in connection with sales of capital equipment that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase order for the equipment. Installation, training and shipping fees related to capital equipment sales not having been preceded by an evaluation period are recognized as revenue at the point in time that the related services are performed.</td></tr></table>   The Company operates in one industry segment, and substantially all its sales are to U.S.-based customers.   Payment terms under contracts with customers generally are in a range of 30-60 days after the customers’ receipt of the Company’s invoices.   The Company provides a one-year warranty on its functional neurosurgery products, biologics and drug delivery systems products, and capital equipment products that are not otherwise covered by a third-party manufacturer’s warranty. The Company’s contracts with customers do not provide for a right of return other than for product defects.   See Note 3 for additional information regarding revenue recognition.   Net Loss Per Share   The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the entire amount of the Company’s outstanding common stock options and warrants, as described in Note 7, and the potential conversion of the 2020 Secured Notes, as described in Note 5, would be anti-dilutive.   Concentration Risks and Other Risks and Uncertainties   Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At June 30, 2020, the Company had approximately $7.9 million in bank balances that were in excess of the insured limits.   Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"> </td><td style="width: 2%; font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 9pt; font-weight: bold; text-align: center">June 30, 2020</td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2019</td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 5.75pt">Customer – 1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">12%</td><td style="text-align: left"> </td></tr> </table>   Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 9pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 60%; text-align: justify; padding-left: 5.75pt">Customer – 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">22%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr> </table>   Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 9pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 60%; text-align: justify; padding-left: 5.75pt">Customer – 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">21%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr> </table>   Prior to granting credit, the Company performs credit evaluations of its customers’ financial condition, and generally does not require collateral from its customers. The Company will provide an allowance for doubtful accounts when collections become doubtful. The allowance for doubtful accounts at June 30, 2020 and December 31, 2019 was approximately $32,000 and $29,000, respectively.   The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 3%; font-family: Times New Roman,serif">3.</td> <td style="width: 1%; font-family: Times New Roman,serif; text-align: justify"> </td> <td style="width: 96%; font-family: Times New Roman,serif; text-align: justify">Revenue Recognition</td></tr> </table>   Revenue by Service Line   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify">Products:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.6pt; padding-left: 5.4pt">Disposable products:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 72%; text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Functional neurosurgery</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,049,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,690,122</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Biologics and drug delivery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,955</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244,949</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Therapy</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,830</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: 18.6pt; padding-left: 5.4pt">Capital equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">115,800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">241,293</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total product revenue</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: right">1,593,070</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,194,194</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Services:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 18.6pt">Capital equipment and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">123,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">243,954</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 18.6pt">Biologics and drug delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">760,714</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">168,250</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total service revenue</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: right">884,712</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">412,204</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 18.7pt; padding-left: 35.9pt">Total revenue</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Calibri,sans-serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Calibri,sans-serif; text-align: right">2,477,782</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,606,398</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 5.4pt">Products:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.6pt; padding-left: 5.4pt">Disposable products:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 72%; text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Functional neurosurgery</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,733,424</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,294,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Biologics and drug delivery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">580,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">529,859</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Therapy</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,830</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: 18.6pt; padding-left: 5.4pt">Capital equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">303,901</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">515,692</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total product revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,696,455</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,358,148</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Services:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 18.6pt">Capital equipment and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280,493</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">455,156</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 18.6pt">Biologics and drug delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,616,428</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">265,611</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total service revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,896,121</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">720,767</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 18.7pt; padding-left: 35.9pt">Total revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,593,376</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,078,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Contract Balances   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">Contract assets – Substantially all the Company’s contracts with customers are based on customer-issued purchase orders for distinct products or services. Customers are billed upon delivery of such products or services, and the related contract assets comprise the accounts receivable balances included in the accompanying condensed consolidated balance sheets.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">Contract liabilities – The Company generally bills and collects capital equipment-related service fees at the inception of the service agreements, which have terms ranging from one to three years. The unearned portion of such service fees are classified as deferred revenue.</td></tr></table>   During the three and six months ended June 30, 2020, the Company recognized capital equipment-related service revenue of approximately $89,000 and $210,000, respectively, which was previously included in deferred revenue in the accompanying condensed consolidated balance sheet at December 31, 2019.   In September 2019, the Company entered into a Development Services Agreement with a customer under which the Company was entitled to bill the customer for an upfront payment of $127,600, of which $83,000 and $102,000 are included in deferred revenue in the accompanying June 30, 2020 and December 31, 2019 condensed consolidated balance sheets, respectively.   Also, in September 2019, the Company entered into a Letter of Intent, followed by a related Statement of Work (together with the Letter of Intent, the “Project Documents”) in November 2019, with a customer which is a stockholder and whose then Chief Operating Officer was a member of the Company’s Board of Directors (and was subsequently replaced with the customer’s Chief Development Officer), to commence a product development project. Under the terms of the Project Documents, the Company was entitled to bill the customer for: (a) an upfront, nonrefundable payment of $500,000; and (b) quarterly service fees of $500,000 commencing in the fourth quarter of 2019. In February 2020, the Company entered into a Supply Agreement and a Statement of Work (the “European SOW”) with a European affiliate of the customer. Under the terms of the European SOW, the Company was entitled to bill the customer on a quarterly basis, commencing in the first quarter of 2020, for service fees of $250,000. During the six months ended June 30, 2020, the clinical trials contemplated by the Project Documents and the European SOW were delayed as a result of the COVID-19 pandemic. As a result, the Company agreed to reduce such quarterly service fees by an aggregate of $100,000 and $200,000 during the three and six months ended June 30, 2020, respectively. The Company recognizes as revenue each of the upfront payments described in this paragraph in proportional relationship to the transaction prices of the performance obligations contained in the related agreements, and recognizes as revenue the quarterly service fees described in this paragraph as stand-by services beginning in the quarter such services commenced. Based on the foregoing, approximately $429,000 and $625,000 of the aggregate amount of all the payments described in this paragraph were included in deferred revenue in the accompanying condensed consolidated balance sheets at June 30, 2020 and December 31, 2019, respectively.   The Company offers an upgraded version of its software at no additional charge to customers purchasing a three-year systems service agreement. The transaction prices of the software and the service agreement are determined through an allocation of the service agreement price based on the standalone prices of the software and the service agreements. The transaction price of the software is recognized as revenue upon its installation and comprised approximately $143,000 and $172,000 of unbilled accounts receivable at June 30, 2020 and December 31, 2019, respectively.   Remaining Performance Obligations   The Company’s contracts with customers, other than capital equipment-related service agreements discussed below, are predominantly of terms less than one year. Accordingly, the transaction price of remaining performance obligations related to such contracts at June 30, 2020 are not material.   Revenue with respect to remaining performance obligations related to capital equipment-related service agreements with original terms in excess of one year and the upfront payments discussed under the heading “Contract Balances” above amounted to approximately $672,000 at June 30, 2020. The Company expects to recognize this revenue within the next three years.

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 24px; font-family: Times New Roman,serif">7.</td> <td style="font-family: Times New Roman,serif; text-align: justify">Stockholders’ Equity</td></tr> </table>   2019 Private Placement   On May 9, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Investors”) for the private placement of 2,426,455 shares of the Company’s common stock at $3.10 per share. The Company received aggregate gross proceeds of approximately $7.5 million, before deducting offering expenses aggregating approximately $94,000.   The Purchase Agreement also contains representations and warranties by the Company and the Investors and covenants of the Company and the Investors (including indemnification from the Company in the event of breaches of its representations and warranties), certain information rights and other rights, obligations and restrictions, which the Company believes are customary for transactions of this type.   Issuance of Common Stock in Lieu of Cash Payments   Under the terms of the Amended and Restated Non-Employee Director Compensation Plan, each compensated non-employee member of the Company’s Board of Directors may elect to receive all or part of his or her director fees in shares of the Company’s common stock. Director fees, whether paid in cash or in shares of common stock, are payable quarterly on the last day of each fiscal quarter. The number of shares of common stock issued to directors is determined by dividing the product of: (i)(a) the fees otherwise payable to each director in cash, times (b) the percentage of fees the director elected to receive in shares of common stock, by (ii) the volume weighted average price per share of common stock over the last five trading days of the quarter. The following is information regarding the number of shares issued to directors as payment for director fees in lieu of cash for the three and six months ended June 30, 2020 and 2019:   <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; background-color: white; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td colspan="4" style="border-bottom: Black 1pt solid; font-family: Times New Roman,serif; text-align: center">Three Months Ended June 30,</td></tr> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 47%; font-family: Times New Roman,serif; text-align: center">2020</td> <td style="vertical-align: top; width: 5%; font-family: Times New Roman,serif"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 41%; font-family: Times New Roman,serif; text-align: center">2019</td> <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 7%; font-family: Times New Roman,serif"> </td></tr> <tr style="background-color: rgb(230,239,255)"> <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center">9,832</td> <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"> </td> <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center">8,841</td> <td style="vertical-align: top; font-family: Times New Roman,serif"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman,serif; text-align: center">Six Months Ended June 30,</td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman,serif; text-align: center">2020</td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman,serif; text-align: center">2019</td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 47%; text-align: center">19,563</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 47%; text-align: center">17,739</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td></tr> </table>   Stock Incentive Plans   The Company has various share-based compensation plans and share-based compensatory contracts (collectively, the “Plans”) under which it has granted share-based awards, such as stock grants, and incentive and non-qualified stock options, to employees, directors, consultants and advisors. Awards may be subject to a vesting schedule as set forth in individual award agreements. Certain of the Plans also have provided for cash-based performance bonus awards.   From October 2017 until June 2020, the Company granted share-based awards under the Company’s Second Amended and Restated 2013 Incentive Compensation Plan (the “Second Amended Plan”). On June 2, 2020, the Company’s stockholders approved the Company’s Third Amended and Restated 2013 Incentive Compensation Plan (the “Third Amended Plan” and, together with the Second Amended Plan, the “2013 Plan”), under which 1 million shares of the Company’s common stock were made available for future issuances under the 2013 Plan, resulting in a total of 2,956,250 shares of the Company’s common stock being reserved for issuance under the 2013 Plan. Of this amount, stock grants of 440,995 shares have been awarded and option grants, net of options terminated, expired or forfeited, of 1,175,679 shares were outstanding as of June 30, 2020. Accordingly, 1,339,576 shares remained available for grants under the 2013 Plan as of that date.   Stock option activity under all of the Company’s Plans during the six months ended June 30, 2020 is summarized below:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman,serif"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Weighted-average Exercise price per share</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: center">Intrinsic Value(1)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; width: 58%">Outstanding at January 1, 2020</td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">1,639,167</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">9.87</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">2,892,027</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman,serif">Granted</td><td style="font: 10pt Times New Roman,serif"> </td> <td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; text-align: right">84,445</td><td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif"> </td> <td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; text-align: right">4.14</td><td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif"> </td> <td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; text-align: right">26,512</td><td style="font: 10pt Times New Roman,serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: right">(833</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right">1.74</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt">Outstanding at June 30, 2020</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: right">1,722,779</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">9.59</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">867,568</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" align="center" style="width: 95%; border-collapse: collapse; font-size: 10pt"> <tr> <td style="vertical-align: top; width: 3%; font-family: Times New Roman,serif; text-align: center">(1)</td> <td style="vertical-align: top; width: 97%; font-family: Times New Roman,serif">Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.</td></tr> </table>   As of June 30, 2020, there was unrecognized compensation expense of $948,807 related to outstanding stock options and shares of restricted stock, which is expected to be recognized over a weighted average period of 1.44 years.   Warrants   Warrants have generally been issued in connection with financing transactions and for terms of up to five years. Common stock warrant activity for the six months ended June 30, 2020 was as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman,serif"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Weighted-average Exercise price per share</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: center">Intrinsic Value(1)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; width: 58%">Outstanding at January 1, 2020</td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">5,532,267</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">4.00</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">10,470,008</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: right">(428,532</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right">2.20</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt">Outstanding at June 30, 2020</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: right">5,103,735</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">4.15</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">2,717,201</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" align="center" style="width: 95%; border-collapse: collapse; font-size: 10pt"> <tr> <td style="vertical-align: top; width: 3%; font-family: Times New Roman,serif; text-align: center">(1)</td> <td style="vertical-align: top; width: 97%; font-family: Times New Roman,serif">Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.</td></tr> </table>

Basis of Presentation and Use of Estimates   In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2019 audited consolidated financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with United States Securities and Exchange Commission (“SEC”) rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2019 Form 10-K. The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for a complete set of financial statements. The results of operations for the three and six months ended June 30, 2020 may not be indicative of the results to be expected for the entire year or any future periods.

Inventory   Inventory is carried at the lower of cost (first-in, first-out method) or net realizable value. Items in inventory relate predominantly to the Company’s ClearPoint system. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for obsolete items and provides a reserve upon identification of potential obsolete items.

Intangible Assets   In June 2019 and February 2020, the Company entered into license agreements that provide rights to the Company for the development and commercialization of products in the functional neurosurgery field. Under the terms of those certain license agreements, the Company paid an aggregate $591,341 to the licensors upon execution of the license agreements for access to the underlying technologies and will make future payments based on the achievement of regulatory and commercialization milestones as defined in the license agreements.   In conformity with Accounting Standards Codification Section 350, “Intangibles – Goodwill and Other,” the Company amortizes its investment in the license rights described above over an expected useful life of five years.

Revenue Recognition   The Company’s revenues are comprised primarily of: (1) product revenues resulting from the sale of functional neurosurgical products, and drug delivery and biologic products; (2) product revenues resulting from the sale of ClearPoint capital equipment; (3) revenues resulting from the rental, service, installation, training and shipping related to ClearPoint capital equipment; and (4) clinical case support revenues in connection with customer-sponsored clinical trials. The Company recognizes revenue when control of the Company’s products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control.   Lines of Business; Timing of Revenue Recognition   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">·</td><td style="text-align: justify">Functional neurosurgery product, biologics and drug delivery systems product, and therapy product sales: Revenues from the sale of functional neurosurgery products (consisting of disposable products sold commercially and related to cases utilizing the Company’s ClearPoint system), biologics and drug delivery systems (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in non-neurosurgical procedures), are generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and are recognized at the point in time of delivery to the customer, which is the point at which legal title, and risks and rewards of ownership, along with physical possession, transfer to the customer.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Capital equipment sales</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Capital equipment sales preceded by evaluation periods: The predominance of capital equipment sales (consisting of integrated computer hardware and software that are integral components of the Company’s ClearPoint system) are preceded by customer evaluation periods of generally 90 days. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment sales following such evaluation periods is recognized at the point in time the Company is in receipt of an executed purchase agreement or purchase order.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Capital equipment sales not preceded by evaluation periods: Revenue from sales of capital equipment not having been preceded by an evaluation period is recognized at the point in time that the equipment has been delivered to the customer.</td></tr></table>   For both types of capital equipment sales described above, the Company’s determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment.   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Functional neurosurgery and related services: Revenues from functional neurosurgery and related services are recognized over the period of time such services are rendered.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Biologics and drug delivery services:</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Outsourced technical clinical support of cases performed pursuant to customer-sponsored clinical trials:</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in">§</td><td style="text-align: justify">Service Access Fees: For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by Company personnel during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in">§</td><td style="text-align: justify">Procedure-Based Fees: The Company recognizes revenue at the point in time a case is attended by Company personnel.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Therapy services: The Company recognizes revenue for such services at the point in time that the performance obligation has been satisfied.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 40.5pt"></td><td style="width: 13.5pt">·</td><td style="text-align: justify">Capital equipment-related services:</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Equipment service: Revenue from service of ClearPoint capital equipment previously sold to customers is based on agreements with terms ranging from one to three years and revenue is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for rental and service revenues because the Company transfers control evenly by providing a stand-ready service.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">Installation, training and shipping: Consistent with the Company’s recognition of revenue for capital equipment sales as described above, fees for installation, training and shipping in connection with sales of capital equipment that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase order for the equipment. Installation, training and shipping fees related to capital equipment sales not having been preceded by an evaluation period are recognized as revenue at the point in time that the related services are performed.</td></tr></table>   The Company operates in one industry segment, and substantially all its sales are to U.S.-based customers.   Payment terms under contracts with customers generally are in a range of 30-60 days after the customers’ receipt of the Company’s invoices.   The Company provides a one-year warranty on its functional neurosurgery products, biologics and drug delivery systems products, and capital equipment products that are not otherwise covered by a third-party manufacturer’s warranty. The Company’s contracts with customers do not provide for a right of return other than for product defects.   See Note 3 for additional information regarding revenue recognition.

Net Loss Per Share   The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the entire amount of the Company’s outstanding common stock options and warrants, as described in Note 7, and the potential conversion of the 2020 Secured Notes, as described in Note 5, would be anti-dilutive.

Concentration Risks and Other Risks and Uncertainties   Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At June 30, 2020, the Company had approximately $7.9 million in bank balances that were in excess of the insured limits.   Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"> </td><td style="width: 2%; font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 9pt; font-weight: bold; text-align: center">June 30, 2020</td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2019</td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 5.75pt">Customer – 1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">12%</td><td style="text-align: left"> </td></tr> </table>   Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 9pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 60%; text-align: justify; padding-left: 5.75pt">Customer – 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">22%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr> </table>   Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 9pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 60%; text-align: justify; padding-left: 5.75pt">Customer – 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">21%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr> </table>   Prior to granting credit, the Company performs credit evaluations of its customers’ financial condition, and generally does not require collateral from its customers. The Company will provide an allowance for doubtful accounts when collections become doubtful. The allowance for doubtful accounts at June 30, 2020 and December 31, 2019 was approximately $32,000 and $29,000, respectively.   The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.

Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"> </td><td style="width: 2%; font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 9pt; font-weight: bold; text-align: center">June 30, 2020</td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 9pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2019</td><td style="width: 1%; padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 5.75pt">Customer – 1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">12%</td><td style="text-align: left"> </td></tr> </table>   Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 9pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 60%; text-align: justify; padding-left: 5.75pt">Customer – 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">22%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr> </table>   Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 9pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 60%; text-align: justify; padding-left: 5.75pt">Customer – 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">21%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify">Products:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.6pt; padding-left: 5.4pt">Disposable products:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 72%; text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Functional neurosurgery</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,049,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,690,122</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Biologics and drug delivery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,955</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244,949</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Therapy</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,830</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: 18.6pt; padding-left: 5.4pt">Capital equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">115,800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">241,293</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total product revenue</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: right">1,593,070</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,194,194</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Services:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 18.6pt">Capital equipment and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">123,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">243,954</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 18.6pt">Biologics and drug delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">760,714</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">168,250</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total service revenue</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Calibri,sans-serif; text-align: right">884,712</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">412,204</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 18.7pt; padding-left: 35.9pt">Total revenue</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Calibri,sans-serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Calibri,sans-serif; text-align: right">2,477,782</td><td style="font: 11pt Calibri,sans-serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,606,398</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 5.4pt">Products:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.6pt; padding-left: 5.4pt">Disposable products:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 72%; text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Functional neurosurgery</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,733,424</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,294,767</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Biologics and drug delivery</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">580,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">529,859</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; text-indent: 18.7pt; padding-left: 17.9pt">Therapy</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,830</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: 18.6pt; padding-left: 5.4pt">Capital equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">303,901</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">515,692</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total product revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,696,455</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,358,148</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Services:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-left: 18.6pt">Capital equipment and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280,493</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">455,156</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 18.6pt">Biologics and drug delivery</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,616,428</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">265,611</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 35.9pt">Total service revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,896,121</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">720,767</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 18.7pt; padding-left: 35.9pt">Total revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,593,376</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,078,915</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">June 30, 2020</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td><td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 72%; text-align: left">Raw materials and work in process</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,761,658</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,495,190</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Software licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">332,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,627,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,412,528</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Inventory, net, included in current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,598,980</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,240,218</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: left; padding-bottom: 1pt">Software licenses – non-current</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">506,800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">504,400</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0.5in"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,105,780</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,744,618</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Years ending December 31,</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="width: 86%; text-align: left">2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">73,984</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">446,504</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">375,512</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="text-align: left">Total scheduled principal payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,396,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Unamortized financing costs and discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(685,901</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="padding-bottom: 2.5pt; padding-left: 0.5in"> Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,710,099</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" align="center" style="width: 50%; background-color: white; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td colspan="4" style="border-bottom: Black 1pt solid; font-family: Times New Roman,serif; text-align: center">Three Months Ended June 30,</td></tr> <tr> <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 47%; font-family: Times New Roman,serif; text-align: center">2020</td> <td style="vertical-align: top; width: 5%; font-family: Times New Roman,serif"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 41%; font-family: Times New Roman,serif; text-align: center">2019</td> <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 7%; font-family: Times New Roman,serif"> </td></tr> <tr style="background-color: rgb(230,239,255)"> <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center">9,832</td> <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"> </td> <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center">8,841</td> <td style="vertical-align: top; font-family: Times New Roman,serif"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman,serif; text-align: center">Six Months Ended June 30,</td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman,serif; text-align: center">2020</td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman,serif; text-align: center">2019</td><td style="font: bold 9pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 47%; text-align: center">19,563</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 47%; text-align: center">17,739</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman,serif"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Weighted-average Exercise price per share</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: center">Intrinsic Value(1)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; width: 58%">Outstanding at January 1, 2020</td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">1,639,167</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">9.87</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">2,892,027</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman,serif">Granted</td><td style="font: 10pt Times New Roman,serif"> </td> <td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; text-align: right">84,445</td><td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif"> </td> <td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; text-align: right">4.14</td><td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif"> </td> <td style="font: 10pt Times New Roman,serif; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; text-align: right">26,512</td><td style="font: 10pt Times New Roman,serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: right">(833</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right">1.74</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt">Outstanding at June 30, 2020</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: right">1,722,779</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">9.59</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">867,568</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" align="center" style="width: 95%; border-collapse: collapse; font-size: 10pt"> <tr> <td style="vertical-align: top; width: 3%; font-family: Times New Roman,serif; text-align: center">(1)</td> <td style="vertical-align: top; width: 97%; font-family: Times New Roman,serif">Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman,serif"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman,serif; text-align: center">Weighted-average Exercise price per share</td><td style="font: bold 10pt Times New Roman,serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: center">Intrinsic Value(1)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; width: 58%">Outstanding at January 1, 2020</td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">5,532,267</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">4.00</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; width: 2%"> </td> <td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; width: 10%; text-align: right">10,470,008</td><td style="font: 10pt Times New Roman,serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt">Exercised</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman,serif; text-align: right">(428,532</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right">2.20</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(230,239,255)"> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt">Outstanding at June 30, 2020</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman,serif; text-align: right">5,103,735</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">4.15</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left">$</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: right">2,717,201</td><td style="font: 10pt Times New Roman,serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" align="center" style="width: 95%; border-collapse: collapse; font-size: 10pt"> <tr> <td style="vertical-align: top; width: 3%; font-family: Times New Roman,serif; text-align: center">(1)</td> <td style="vertical-align: top; width: 97%; font-family: Times New Roman,serif">Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.</td></tr> </table>

313476

201503

73746

137931

959661

200000 100000

56438

28219

28617

55620

9.87

9.59

2892027

867568

833

4.14

1.74

26512

5532267

5103735

428532

4.00 4.15 2.20

10470008

2717201

948807

P1Y6M

P5Y

10336360

4360515

Yes

197000

2800000

480395 480395

94000

163321 Intrinsic value is calculated as the estimated fair value of the Company's stock at the end of the related period less the option exercise price of in-the-money options.

EX-101.SCH 6 clpt-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of the Business and Financial Condition link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Description of the Business and Financial Condition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenue Recognition - Schedule of Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Revenue Recognition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Inventory - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes Payable - Schedule of Notes Payable Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders' Equity - Schedule of Shares Issued to Directors (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stockholders' Equity - Schedule of Stock Options Issued by the Company (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 clpt-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 clpt-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 clpt-20200630_lab.xml XBRL LABEL FILE Long-term Debt, Type [Axis] 2014 Junior Secured Notes Payable Net 2010 Senior Secured Convertible Notes Payable Net Product and Service [Axis] Capital Equipment-Related Service Revenue Concentration Risk Benchmark [Axis] Accounts Receivable Concentration Risk Type [Axis] Customer #1 Sales Range [Axis] Maximum Minimum Debt Instrument [Axis] 2010 Junior Secured Notes Payable Title of Individual [Axis] Chairman and Officer Plan Name [Axis] Amended and Restated 2013 Incentive Compensation Plan Type of Arrangement and Non-arrangement Transactions [Axis] Securities Purchase Agreement (the "2019 PIPE") Related Party [Axis] Accredited Investors Security Purchase Agreement The "2020 Secured Notes" Product - Functional Neurosurgery Product - Biologics and Drug Delivery Product - Capital Equipment Services - Biologics and Drug Delivery Services - Capital Equipment and Other Products - Therapy Remaining Performance Obligations Capital Equipment-Related Service Revenue Development Services Agreement Letter of Intent Investor Property, Plant and Equipment, Type [Axis] Office Lease - Irvine, California Office Lease - Mississauga, Ontario, Canada SBA's Payroll Protection Program Research and Development Arrangement, Contract to Perform for Others, Type [Axis] License Agreement Terms Billing Status, Type [Axis] Nonrefundable Payment Director The "2020 Convertible Noteholders" Product Revenue Service and Other Revenues Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Third Amended and Restated 2013 Incentive Compensation Plan Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Entity File Number Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Interactive Data Current Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Small Business Entity Emerging Growth Company Entity Filer Category Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash and cash equivalents Accounts receivable, net Inventory, net Prepaid expenses and other current assets Total current assets Property and equipment, net Operating lease rights of use Software license inventory Licensing rights Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued compensation Other accrued liabilities Operating lease liabilities, current portion Deferred product and service revenue Paycheck Protection Program loan payable, current portion Total current liabilities Accrued interest Operating lease liabilities, net of current portion Deferred product and service revenue, net of current portion Secured notes payable, net Paycheck Protection Program loan payable, net of current portion Total liabilities Commitments and contingencies Stockholders' equity: Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2020 and December 31, 2019 Common stock, $0.01 par value; 200,000,000 shares authorized; 15,507,149 shares issued and outstanding at Mach 31, 2020; and 15,235,308 shares issued and outstanding at December 31, 2019 Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Statement of Financial Position [Abstract] Unamortized discount Aggregate unamortized discount and deferred issuance costs Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Revenues: Total revenues Cost of revenues Research and development costs Sales and marketing expenses General and administrative expenses Operating loss Other income (expense): Other income (expense), net Interest expense, net Net loss Net loss per share attributable to common stockholders: Basic and diluted (in dollars per share) Weighted average shares outstanding: Basic and diluted (in shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Balances at beginning Balances at beginning (in shares) Cumulative adjustment for adoption of new accounting standard Share-based compensation Share-based compensation (in shares) Under contractual arrangements Under contractual arrangements (in shares) Warrant exercises Warrant exercises (in shares) Private placement net of offering costs Private placement (in shares) Net loss for the period Balances at ending Balance at ending (in shares) Statement of Stockholders' Equity [Abstract] Private placement offering costs Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash flows from operating activities: Depreciation and amortization Share-based compensation Amortization of debt issuance costs and original issue discounts Amortization of lease right of use, net of accretion in lease liabilities Increase (decrease) in cash resulting from changes in: Accounts receivable Inventory, net Prepaid expenses and other current assets Other assets Accounts payable and accrued expenses Accrued interest Lease liabilities Deferred revenue Net cash flows from operating activities Cash flows from investing activities: Acquisition of licensing rights Net cash flows from investing activities Cash flows from financing activities: Proceeds from issuance of 2020 senior secured convertible notes, net of financing costs and discount Proceeds from issuance of Paycheck Protection Program loan Proceeds from private placement of common stock Proceeds from stock option warrant exercises Repayment of notes payable Net cash flows from financing activities Net change in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for: Income taxes Interest Non-Cash Transactions Operating lease right-of-use assets Operating lease liabilities Aggregate net book value of reusable components transferred from inventory to loaned systems Aggregate net book value of reusable components transferred from loaned systems to inventory Financing costs EX-101.PRE 10 clpt-20200630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 10, 2020
Document And Entity Information
Entity Registrant Name	ClearPoint Neuro, Inc.
Entity Central Index Key	0001285550
Document Type	10-Q
Entity File Number	001-34822
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Interactive Data Current	Yes
Entity's Reporting Status Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,731,352
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 16,032,082	$ 5,695,722
Accounts receivable, net	1,163,663	1,089,917
Inventory, net	3,598,980	3,240,218
Prepaid expenses and other current assets	537,940	357,227
Total current assets	21,332,665	10,383,084
Property and equipment, net	342,584	447,162
Operating lease rights of use	321,155	374,218
Software license inventory	506,800	504,400
Licensing rights	517,207	135,000
Other assets	12,438	82,573
Total assets	23,032,849	11,926,437
Current liabilities:
Accounts payable	1,491,377	965,783
Accrued compensation	969,877	1,408,292
Other accrued liabilities	334,627	328,460
Operating lease liabilities, current portion	110,914	113,520
Deferred product and service revenue	620,126	1,016,892
Paycheck Protection Program loan payable, current portion	296,677
Total current liabilities	3,823,598	3,832,947
Accrued interest		959,659
Operating lease liabilities, net of current portion	227,714	276,669
Deferred product and service revenue, net of current portion	228,286	197,862
Paycheck Protection Program loan payable, net of current portion	599,323
Total liabilities	21,693,020	7,339,720
Stockholders' equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2020 and December 31, 2019
Common stock, $0.01 par value; 200,000,000 shares authorized; 15,507,149 shares issued and outstanding at Mach 31, 2020; and 15,235,308 shares issued and outstanding at December 31, 2019	155,127	152,353
Additional paid-in capital	117,640,195	117,173,984
Accumulated deficit	(116,455,493)	(112,739,620)
Total stockholders' equity	1,339,829	4,586,717
Total liabilities and stockholders' equity	23,032,849	11,926,437
2010 Senior Secured Convertible Notes Payable Net
Current liabilities:
Secured notes payable, net	$ 16,814,099
2014 Junior Secured Notes Payable Net
Current liabilities:
Secured notes payable, net		$ 2,072,583

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized	25,000,000	25,000,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	15,512,687	15,235,308
Common stock, outstanding	15,512,687	15,235,308

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenues	$ 2,477,782	$ 2,606,398	$ 5,593,376	$ 5,078,915
Cost of revenues	640,805	1,030,316	1,558,141	1,916,798
Research and development costs	822,301	697,803	1,651,829	1,282,343
Sales and marketing expenses	1,124,378	1,143,056	2,422,972	2,183,769
General and administrative expenses	1,365,084	1,028,291	2,643,592	1,961,322
Operating loss	(1,474,786)	(1,293,068)	(2,683,158)	(2,265,317)
Other income (expense):
Other income (expense), net	10,851	1,693	6,131	7,322
Interest expense, net	(197,113)	(259,020)	(1,038,846)	(513,125)
Net loss	$ (1,661,048)	$ (1,550,395)	$ (3,715,873)	$ (2,771,120)
Net loss per share attributable to common stockholders:
Basic and diluted (in dollars per share)	$ (0.11)	$ (0.13)	$ (0.24)	$ (0.24)
Weighted average shares outstanding:
Basic and diluted (in shares)	15,504,169	12,302,667	15,471,222	11,676,872
Product Revenue
Revenues:
Total revenues	$ 1,593,070	$ 2,194,194	$ 3,696,455	$ 4,358,148
Service and Other Revenues
Revenues:
Total revenues	$ 884,712	$ 412,204	$ 1,896,921	$ 720,767

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balances at beginning at Dec. 31, 2018	$ 110,183	$ 108,600,405	$ (107,199,586)	$ 1,511,002
Balances at beginning (in shares) at Dec. 31, 2018	11,018,364
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative adjustment for adoption of new accounting standard			(244)	(244)
Share-based compensation	$ 285	152,301		152,586
Share-based compensation (in shares)	28,462
Warrant exercises	$ 204	(204)
Warrant exercises (in shares)	20,381
Net loss for the period			(1,220,725)	(1,220,725)
Balances at ending at Mar. 31, 2019	$ 110,672	108,752,502	(108,420,555)	442,619
Balance at ending (in shares) at Mar. 31, 2019	11,067,207
Balances at beginning at Dec. 31, 2018	$ 110,183	108,600,405	(107,199,586)	1,511,002
Balances at beginning (in shares) at Dec. 31, 2018	11,018,364
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss for the period				(2,771,120)
Balances at ending at Jun. 30, 2019	$ 136,863	116,741,229	(109,970,950)	6,907,142
Balance at ending (in shares) at Jun. 30, 2019	13,686,320
Balances at beginning at Mar. 31, 2019	$ 110,672	108,752,502	(108,420,555)	442,619
Balances at beginning (in shares) at Mar. 31, 2019	11,067,207
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative adjustment for adoption of new accounting standard			(244)	(244)
Share-based compensation	$ 32	203,962		203,994
Share-based compensation (in shares)	3,251
Warrant exercises	$ 1,894	381,182		383,076
Warrant exercises (in shares)	189,407
Private placement net of offering costs	$ 24,265	7,403,583		7,427,848
Private placement (in shares)	2,426,455
Net loss for the period			(1,550,395)	(1,550,395)
Balances at ending at Jun. 30, 2019	$ 136,863	116,741,229	(109,970,950)	6,907,142
Balance at ending (in shares) at Jun. 30, 2019	13,686,320
Balances at beginning at Dec. 31, 2019	$ 152,353	117,173,984	(112,739,620)	4,586,717
Balances at beginning (in shares) at Dec. 31, 2019	15,235,308
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	$ 97	227,871		227,968
Share-based compensation (in shares)	9,696
Warrant exercises	$ 2,621	(2,621)
Warrant exercises (in shares)	262,145
Net loss for the period			(2,054,825)	(2,054,825)
Balances at ending at Mar. 31, 2020	$ 155,071	117,399,234	(114,794,445)
Balance at ending (in shares) at Mar. 31, 2020	15,507,149
Balances at beginning at Dec. 31, 2019	$ 152,353	117,173,984	(112,739,620)	4,586,717
Balances at beginning (in shares) at Dec. 31, 2019	15,235,308
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss for the period				(3,715,873)
Balances at ending at Jun. 30, 2020	$ 155,127	117,640,195	(116,455,493)	1,339,829
Balance at ending (in shares) at Jun. 30, 2020	15,512,687
Balances at beginning at Mar. 31, 2020	$ 155,071	117,399,234	(114,794,445)
Balances at beginning (in shares) at Mar. 31, 2020	15,507,149
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	$ 56	240,961		241,017
Share-based compensation (in shares)	5,538
Net loss for the period			(1,661,048)	(1,661,048)
Balances at ending at Jun. 30, 2020	$ 155,127	$ 117,640,195	$ (116,455,493)	$ 1,339,829
Balance at ending (in shares) at Jun. 30, 2020	15,512,687

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)	3 Months Ended
	Jun. 30, 2019 USD ($)
Statement of Stockholders' Equity [Abstract]
Private placement offering costs	$ 94,162

XML 17 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (3,715,873)	$ (2,771,120)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	116,026	69,600
Share-based compensation	468,985	356,580
Amortization of debt issuance costs and original issue discounts	821,301	363,465
Amortization of lease right of use, net of accretion in lease liabilities	49,782	51,255
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(73,746)	(137,931)
Inventory, net	(313,476)	(201,503)
Prepaid expenses and other current assets	(180,712)	(216,953)
Other assets	70,134	11,899
Accounts payable and accrued expenses	93,347	716,222
Accrued interest	(959,661)
Lease liabilities	(48,280)	(50,285)
Deferred revenue	(366,341)	389,201
Net cash flows from operating activities	(4,038,514)	(1,419,570)
Cash flows from investing activities:
Acquisition of licensing rights	(441,341)	(150,000)
Net cash flows from investing activities	(441,341)	(150,000)
Cash flows from financing activities:
Proceeds from issuance of 2020 senior secured convertible notes, net of financing costs and discount	16,757,871
Proceeds from issuance of Paycheck Protection Program loan	896,000
Proceeds from private placement of common stock		7,522,010
Proceeds from stock option warrant exercises		383,075
Repayment of notes payable	(2,837,656)	(1,975,000)
Net cash flows from financing activities	14,816,215	5,930,085
Net change in cash and cash equivalents	10,336,360	4,360,515
Cash and cash equivalents, beginning of period	5,695,722	3,101,133
Cash and cash equivalents, end of period	16,032,082	7,461,648
Cash paid for:
Interest	1,043,371	164,157
Non-Cash Transactions
Operating lease right-of-use assets		480,395
Operating lease liabilities		480,395
Aggregate net book value of reusable components transferred from inventory to loaned systems	$ 47,686
Aggregate net book value of reusable components transferred from loaned systems to inventory		163,321
Financing costs		$ 94,000

XML 18 R8.htm IDEA: XBRL DOCUMENT

Description of the Business and Financial Condition

6 Months Ended

Jun. 30, 2020

Description Of Business And Liquidity

Description of the Business and Financial Condition

1.	Description of the Business and Financial Condition

COVID-19

Liquidity

XML 19 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2.	Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

Inventory

Intangible Assets

Revenue Recognition

Lines of Business; Timing of Revenue Recognition

Capital equipment sales

Functional neurosurgery and related services: Revenues from functional neurosurgery and related services are recognized over the period of time such services are rendered.

Biologics and drug delivery services:

Outsourced technical clinical support of cases performed pursuant to customer-sponsored clinical trials:

Procedure-Based Fees: The Company recognizes revenue at the point in time a case is attended by Company personnel.

Therapy services: The Company recognizes revenue for such services at the point in time that the performance obligation has been satisfied.

Capital equipment-related services:

The Company operates in one industry segment, and substantially all its sales are to U.S.-based customers.

Payment terms under contracts with customers generally are in a range of 30-60 days after the customers’ receipt of the Company’s invoices.

See Note 3 for additional information regarding revenue recognition.

Net Loss Per Share

Concentration Risks and Other Risks and Uncertainties

Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:

			June 30, 2020				December 31, 2019
Customer – 1			—				12%

Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		22%		—

Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		21%		—

XML 20 R10.htm IDEA: XBRL DOCUMENT

Revenue Recognition

6 Months Ended

Jun. 30, 2020

Revenue Recognition [Abstract]

Revenue Recognition

Revenue Recognition

Revenue by Service Line

	Three Months Ended June 30,
	2020		2019
Products:
Disposable products:
Functional neurosurgery	$	1,049,015	$	1,690,122
Biologics and drug delivery		406,955		244,949
Therapy		21,300		17,830
Capital equipment		115,800		241,293
Total product revenue		1,593,070		2,194,194
Services:
Capital equipment and other		123,998		243,954
Biologics and drug delivery		760,714		168,250
Total service revenue		884,712		412,204
Total revenue	$	2,477,782	$	2,606,398

	Six Months Ended June 30,
	2020		2019
Products:
Disposable products:
Functional neurosurgery	$	2,733,424	$	3,294,767
Biologics and drug delivery		580,330		529,859
Therapy		78,800		17,830
Capital equipment		303,901		515,692
Total product revenue		3,696,455		4,358,148
Services:
Capital equipment and other		280,493		455,156
Biologics and drug delivery		1,616,428		265,611
Total service revenue		1,896,121		720,767
Total revenue	$	5,593,376	$	5,078,915

Contract Balances

Remaining Performance Obligations

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Inventory

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventory

4.	Inventory

Inventory consists of the following as of:

	June 30, 2020		December 31, 2019
Raw materials and work in process	$	1,761,658	$	1,495,190
Software licenses		210,000		332,500
Finished goods		1,627,322		1,412,528
Inventory, net, included in current assets		3,598,980		3,240,218
Software licenses – non-current		506,800		504,400
Total	$	4,105,780	$	3,744,618

XML 22 R12.htm IDEA: XBRL DOCUMENT

Notes Payable

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Notes Payable

5.	Notes Payable

2020 Secured Notes

Payroll Protection Program Loan

2010 Secured Notes

Scheduled Notes Payable Maturities

Scheduled principal payments as of June 30, 2020 with respect to notes payable are summarized as follows:

Years ending December 31,
2020	$	73,984
2021		446,504
2022		375,512
2023		—
2024		—
Thereafter		17,500,000
Total scheduled principal payments		18,396,000
Less: Unamortized financing costs and discount		(685,901	)
Total	$	17,710,099

XML 23 R13.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

6.	Leases

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2020

Stockholders' equity:

Stockholders' Equity

7.	Stockholders’ Equity

2019 Private Placement

Issuance of Common Stock in Lieu of Cash Payments

Three Months Ended June 30,
2020		2019
9,832		8,841

Six Months Ended June 30,
2020		2019
	19,563		17,739

Stock Incentive Plans

Stock option activity under all of the Company’s Plans during the six months ended June 30, 2020 is summarized below:

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾
Outstanding at January 1, 2020		1,639,167		$	9.87	$	2,892,027
Granted		84,445			4.14		26,512
Exercised		(833	)		1.74
Outstanding at June 30, 2020		1,722,779		$	9.59	$	867,568

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

Warrants

Warrants have generally been issued in connection with financing transactions and for terms of up to five years. Common stock warrant activity for the six months ended June 30, 2020 was as follows:

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾
Outstanding at January 1, 2020		5,532,267		$	4.00	$	10,470,008
Exercised		(428,532	)		2.20
Outstanding at June 30, 2020		5,103,735		$	4.15	$	2,717,201

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Use of Estimates

Basis of Presentation and Use of Estimates

Inventory

Inventory

Intangible Assets

Intangible Assets

Revenue Recognition

Revenue Recognition

Lines of Business; Timing of Revenue Recognition

Capital equipment sales

Functional neurosurgery and related services: Revenues from functional neurosurgery and related services are recognized over the period of time such services are rendered.

Biologics and drug delivery services:

Outsourced technical clinical support of cases performed pursuant to customer-sponsored clinical trials:

Procedure-Based Fees: The Company recognizes revenue at the point in time a case is attended by Company personnel.

Therapy services: The Company recognizes revenue for such services at the point in time that the performance obligation has been satisfied.

Capital equipment-related services:

The Company operates in one industry segment, and substantially all its sales are to U.S.-based customers.

Payment terms under contracts with customers generally are in a range of 30-60 days after the customers’ receipt of the Company’s invoices.

See Note 3 for additional information regarding revenue recognition.

Net Loss Per Share

Net Loss Per Share

Concentration Risks and Other Risks and Uncertainties

Concentration Risks and Other Risks and Uncertainties

Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:

			June 30, 2020				December 31, 2019
Customer – 1			—				12%

Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		22%		—

Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		21%		—

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Schedule of concentration of risk

Information with respect to accounts receivable from those customers who comprised more than 10% of accounts receivable at June 30, 2020 and December 31, 2019 is as follows:

			June 30, 2020				December 31, 2019
Customer – 1			—				12%

Information with respect to customers that accounted for sales in excess of 10% of total sales in the three-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		22%		—

Information with respect to customers that accounted for sales in excess of 10% of total sales in the six-month periods ended June 30, 2020 and 2019 is as follows:

	June 30,
	2020		2019
Customer – 1		21%		—

XML 27 R17.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2020

Revenue Recognition [Abstract]

Schedule of revenue recognition

	Three Months Ended June 30,
	2020		2019
Products:
Disposable products:
Functional neurosurgery	$	1,049,015	$	1,690,122
Biologics and drug delivery		406,955		244,949
Therapy		21,300		17,830
Capital equipment		115,800		241,293
Total product revenue		1,593,070		2,194,194
Services:
Capital equipment and other		123,998		243,954
Biologics and drug delivery		760,714		168,250
Total service revenue		884,712		412,204
Total revenue	$	2,477,782	$	2,606,398

	Six Months Ended June 30,
	2020		2019
Products:
Disposable products:
Functional neurosurgery	$	2,733,424	$	3,294,767
Biologics and drug delivery		580,330		529,859
Therapy		78,800		17,830
Capital equipment		303,901		515,692
Total product revenue		3,696,455		4,358,148
Services:
Capital equipment and other		280,493		455,156
Biologics and drug delivery		1,616,428		265,611
Total service revenue		1,896,121		720,767
Total revenue	$	5,593,376	$	5,078,915

XML 28 R18.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Schedule of inventory

	June 30, 2020		December 31, 2019
Raw materials and work in process	$	1,761,658	$	1,495,190
Software licenses		210,000		332,500
Finished goods		1,627,322		1,412,528
Inventory, net, included in current assets		3,598,980		3,240,218
Software licenses – non-current		506,800		504,400
Total	$	4,105,780	$	3,744,618

XML 29 R19.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Schedule of notes payable maturities

Years ending December 31,
2020	$	73,984
2021		446,504
2022		375,512
2023		—
2024		—
Thereafter		17,500,000
Total scheduled principal payments		18,396,000
Less: Unamortized financing costs and discount		(685,901	)
Total	$	17,710,099

XML 30 R20.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2020

Stockholders' equity:

Schedule of shares issued to directors

Three Months Ended June 30,
2020		2019
9,832		8,841

Six Months Ended June 30,
2020		2019
	19,563		17,739

Schedule of stock options issued by the Company

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾
Outstanding at January 1, 2020		1,639,167		$	9.87	$	2,892,027
Granted		84,445			4.14		26,512
Exercised		(833	)		1.74
Outstanding at June 30, 2020		1,722,779		$	9.59	$	867,568

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

Schedule of common stock warrant activity

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾
Outstanding at January 1, 2020		5,532,267		$	4.00	$	10,470,008
Exercised		(428,532	)		2.20
Outstanding at June 30, 2020		5,103,735		$	4.15	$	2,717,201

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Description of the Business and Financial Condition (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cumulative net loss		$ (116,455,493)		$ (112,739,620)
Net cash used in operations		(4,038,514)	$ (1,419,570)	$ (2,849,515)
Offering costs	$ 94,162
Proceeds from issuance of Paycheck Protection Program loan		896,000
Security Purchase Agreement \| The "2020 Secured Notes"
Secured convertible notes		17,500,000
Proceeds from debt, net		$ 16,800,000
Term of secured notes		5 years
Securities Purchase Agreement (the "2019 PIPE") \| Accredited Investors
Sale of stock, number of shares issued				2,426,455
Share price (in dollars per share)				$ 3.10
Offering costs				$ 94,000
Proceeds from issuance of stock				$ 7,500,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) - Customer #1	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Accounts Receivable
Concentration risk, percentage					12.00%
Sales
Concentration risk, percentage	22.00%		21.00%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative)	6 Months Ended
	Jun. 30, 2020 USD ($) Integer	Dec. 31, 2019 USD ($)
Bank balances in excess of insured limits, approximate	$ 7,900,000
Allowance for doubtful accounts	$ 32,000	$ 29,000
Payment terms under contracts with customers	A range of 30-60 days after the customers' receipt of the Company's invoices.
Operating segments \| Integer	1
Minimum
Term of service agreements (in years)	1 year
Maximum
Term of service agreements (in years)	3 years
License Agreement Terms
Payment terms under license agreement	$ 591,341
Expected useful life	5 years

XML 34 R24.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Schedule of Revenue Recognition (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total revenues	$ 2,477,782	$ 2,606,398	$ 5,593,376	$ 5,078,915
Product - Functional Neurosurgery
Total revenues	1,049,015	1,690,122	2,733,424	3,294,767
Product - Biologics and Drug Delivery
Total revenues	406,955	244,949	580,330	529,859
Products - Therapy
Total revenues	21,300	17,830	78,800	17,830
Product - Capital Equipment
Total revenues	115,800	241,293	303,901	515,692
Product Revenue
Total revenues	1,593,070	2,194,194	3,696,455	4,358,148
Services - Capital Equipment and Other
Total revenues	123,998	243,954	280,493	455,156
Services - Biologics and Drug Delivery
Total revenues	760,714	168,250	1,616,428	265,611
Service and Other Revenues
Total revenues	$ 884,712	$ 412,204	$ 1,896,921	$ 720,767

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Revenue Recognition (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Total revenues	$ 2,477,782	$ 2,606,398	$ 5,593,376	$ 5,078,915
Unbilled accounts receivable	143,000		143,000		$ 172,000
Development Services Agreement
Accounts receivable					127,600
Deferred revenue	83,000		83,000		102,000
Letter of Intent \| Investor
Deferred revenue	429,000		429,000		625,000
Service fees receivable, quarterly	250,000		250,000		500,000
Reduction of service fees receivable	100,000		200,000
Letter of Intent \| Investor \| Nonrefundable Payment
Accounts receivable and deferred revenue					$ 500,000
Remaining Performance Obligations Capital Equipment-Related Service Revenue
Total revenues			672,000
Capital Equipment-Related Service Revenue
Total revenues	$ 89,000		$ 210,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials and work in process	$ 1,761,658	$ 1,495,190
Software licenses	210,000	332,500
Finished goods	1,627,322	1,412,528
Inventory included in current assets	3,598,980	3,240,218
Software licenses - non-current	506,800	504,400
Total inventory	$ 4,105,780	$ 3,744,618

XML 37 R27.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable Maturities (Details)	Jun. 30, 2020 USD ($)
Debt Disclosure [Abstract]
2020	$ 73,984
2021	446,504
2022	375,512
2023
2024
Thereafter	17,500,000
Total scheduled principal payments	18,396,000
Less: Unamortized financing costs and discount	(685,901)
Total	$ 17,710,099

XML 38 R28.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)	6 Months Ended
Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt instrument, unamortized discount	$ 685,901
Proceeds received through a loan funded under the PPP	896,000
2010 Junior Secured Notes Payable
Debt Instrument [Line Items]
Repayment of secured debt	2,800,000
Payments for accrued interest	920,000
Debt face amount		$ 2,800,000
Debt instrument, unamortized discount		765,073
2010 Junior Secured Notes Payable \| Chairman and Officer
Debt Instrument [Line Items]
Debt face amount		$ 197,000
SBA's Payroll Protection Program
Debt Instrument [Line Items]
Proceeds received through a loan funded under the PPP	$ 896,000
Term of PPP loan	2 years
Interest rate	1.00%
Payment terms	Payable monthly from November 2020 through the remainder of the note’s term in equal monthly installments of principal and interest amounting to $50,424.18.
Security Purchase Agreement \| The "2020 Secured Notes"
Debt Instrument [Line Items]
Secured notes	$ 17,500,000
Term of secured notes	5 years
Interest rate terms	Bears interest at a rate equal to the sum of (i) the greater of (x) the three (3)-month London Interbank Offered Rate and (y) two percent (2%), plus (ii) a margin of 2% on the outstanding balance of the 2020 Notes, payable quarterly on the first business day of each calendar quarter.
Conversion price, per share	$ 6.00
Debt instrument, unamortized discount	$ 408,631
Security Purchase Agreement \| The "2020 Convertible Noteholders"
Debt Instrument [Line Items]
Secured convertible notes, terms and conditions	At any time on or prior to January 11, 2022, the Company shall have the right, but not the obligation, to request that one of the 2020 Convertible Noteholders purchase an additional $5,000,000 in aggregate principal amount of Second Closing Notes (as defined in the SPA) and an additional $10,000,000 in aggregate principal amount of additional Third Closing Notes (as defined in the SPA) (together, the “Additional Convertible Notes”), provided that the such 2020 Convertible Noteholder has the right, but not the obligation, to purchase such notes. The terms of the Additional Convertible Notes are the same as the terms of the 2020 Secured Notes, except that: (a) the Additional Convertible Notes would bear interest at a rate equal to the sum of (i) the greater of (x) the three (3)-month London Interbank Offered Rate and (y) 2%, plus (ii) a margin of 7% on their outstanding balance; and (b) only 70% of the Additional Convertible Notes’ principal amount outstanding would be convertible into shares of the Company’s common stock.
Debt instrument, unamortized discount	$ 277,270

XML 39 R29.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Leases (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lease cost (included in general and administrative expense)	$ 28,219	$ 28,617	$ 56,438	$ 55,620
Office Lease - Irvine, California
Commenced date			Oct. 01, 2018
Lease expiration date			Sep. 30, 2023
Lease term	5 years		5 years
Lease renewal term	5 years		5 years
Office Lease - Mississauga, Ontario, Canada
Commenced date			Aug. 01, 2018
Lease expiration date			Jul. 31, 2021
Lease term	1 year		1 year
Lease renewal term	1 year		1 year

XML 40 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Shares Issued to Directors (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Director
Number of shares issued as payment for director fees in lieu of cash	9,832	8,841	19,563	17,739

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock Options Issued by the Company (Details)

6 Months Ended

Jun. 30, 2020

USD ($)

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Outstanding at beginning | shares

1,639,167

Granted | shares

84,445

Exercised | shares

(833)

Outstanding at ending | shares

1,722,779

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding at beginning | $ / shares

$ 9.87

Granted | $ / shares

4.14

Exercised | $ / shares

1.74

Outstanding at ending | $ / shares

$ 9.59

Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]

Outstanding at beginning | $

$ 2,892,027

^[1]

Granted | $

26,512

^[1]

Outstanding at ending | $

$ 867,568

^[1]

[1]	Intrinsic value is calculated as the estimated fair value of the Company's stock at the end of the related period less the option exercise price of in-the-money options.

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Details)

6 Months Ended

Jun. 30, 2020

USD ($)

$ / shares

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Outstanding at beginning | shares

5,532,267

Exercised | shares

(428,532)

Outstanding at ending | shares

5,103,735

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding at beginning | $ / shares

$ 4.00

Exercised | $ / shares

2.20

Outstanding at ending | $ / shares

$ 4.15

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]

Outstanding at beginning | $

$ 10,470,008

^[1]

Outstanding at ending | $

$ 2,717,201

^[1]

[1]	Intrinsic value is calculated as the estimated fair value of the Company's stock at the end of the related period less the option exercise price of in-the-money options.

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019	Jun. 02, 2020
Number of awards oustanding		1,722,779	1,639,167
Number of awards granted		84,445
Unrecognized compensation expense		$ 948,807
Compensation expense, period for recognition		1 year 6 months
Offering costs	$ 94,162
Term of warrants		5 years
Securities Purchase Agreement (the "2019 PIPE") \| Accredited Investors
Sale of stock, number of shares issued			2,426,455
Offering costs			$ 94,000
Share price (in dollars per share)			$ 3.10
Proceeds from issuance of stock			$ 7,500,000
Amended and Restated 2013 Incentive Compensation Plan
Common stock reserved for issuance		2,956,250
Number of share available for grant		1,339,576
Number of awards oustanding		1,175,679
Number of awards granted		440,995
Third Amended and Restated 2013 Incentive Compensation Plan
Common stock reserved for issuance				1,000,000

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 119 269 1 true 38 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://clearpointneuro.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://clearpointneuro.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://clearpointneuro.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://clearpointneuro.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://clearpointneuro.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://clearpointneuro.com/role/StatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://clearpointneuro.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Description of the Business and Financial Condition Sheet http://clearpointneuro.com/role/DescriptionOfBusinessAndLiquidity Description of the Business and Financial Condition Notes 8 false false R9.htm 00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://clearpointneuro.com/role/SummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Revenue Recognition Sheet http://clearpointneuro.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 00000011 - Disclosure - Inventory Sheet http://clearpointneuro.com/role/Inventory Inventory Notes 11 false false R12.htm 00000012 - Disclosure - Notes Payable Notes http://clearpointneuro.com/role/NotesPayable Notes Payable Notes 12 false false R13.htm 00000013 - Disclosure - Leases Sheet http://clearpointneuro.com/role/Leases Leases Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity Sheet http://clearpointneuro.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://clearpointneuro.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://clearpointneuro.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://clearpointneuro.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables 16 false false R17.htm 00000018 - Disclosure - Revenue Recognition (Tables) Sheet http://clearpointneuro.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://clearpointneuro.com/role/RevenueRecognition 17 false false R18.htm 00000019 - Disclosure - Inventory (Tables) Sheet http://clearpointneuro.com/role/InventoryTables Inventory (Tables) Tables http://clearpointneuro.com/role/Inventory 18 false false R19.htm 00000020 - Disclosure - Notes Payable (Tables) Notes http://clearpointneuro.com/role/NotesPayableTables Notes Payable (Tables) Tables http://clearpointneuro.com/role/NotesPayable 19 false false R20.htm 00000021 - Disclosure - Stockholders' Equity (Tables) Sheet http://clearpointneuro.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://clearpointneuro.com/role/StockholdersEquity 20 false false R21.htm 00000022 - Disclosure - Description of the Business and Financial Condition (Details Narrative) Sheet http://clearpointneuro.com/role/DescriptionOfBusinessAndFinancialConditionDetailsNarrative Description of the Business and Financial Condition (Details Narrative) Details http://clearpointneuro.com/role/DescriptionOfBusinessAndLiquidity 21 false false R22.htm 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) Sheet http://clearpointneuro.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) Details 22 false false R23.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://clearpointneuro.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://clearpointneuro.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000025 - Disclosure - Revenue Recognition - Schedule of Revenue Recognition (Details) Sheet http://clearpointneuro.com/role/RevenueRecognition-ScheduleOfRevenueRecognitionDetails Revenue Recognition - Schedule of Revenue Recognition (Details) Details 24 false false R25.htm 00000026 - Disclosure - Revenue Recognition (Details Narrative) Sheet http://clearpointneuro.com/role/RevenueRecognitionDetailsNarrative Revenue Recognition (Details Narrative) Details http://clearpointneuro.com/role/RevenueRecognitionTables 25 false false R26.htm 00000027 - Disclosure - Inventory - Schedule of Inventory (Details) Sheet http://clearpointneuro.com/role/InventoryDetails Inventory - Schedule of Inventory (Details) Details 26 false false R27.htm 00000028 - Disclosure - Notes Payable - Schedule of Notes Payable Maturities (Details) Notes http://clearpointneuro.com/role/NotesPayableDetails Notes Payable - Schedule of Notes Payable Maturities (Details) Details 27 false false R28.htm 00000029 - Disclosure - Notes Payable (Details Narrative) Notes http://clearpointneuro.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://clearpointneuro.com/role/NotesPayableTables 28 false false R29.htm 00000030 - Disclosure - Leases (Details Narrative) Sheet http://clearpointneuro.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://clearpointneuro.com/role/Leases 29 false false R30.htm 00000031 - Disclosure - Stockholders' Equity - Schedule of Shares Issued to Directors (Details) Sheet http://clearpointneuro.com/role/StockholdersEquity-ScheduleOfSharesIssuedToDirectorsDetails Stockholders' Equity - Schedule of Shares Issued to Directors (Details) Details 30 false false R31.htm 00000032 - Disclosure - Stockholders' Equity - Schedule of Stock Options Issued by the Company (Details) Sheet http://clearpointneuro.com/role/StockholdersEquityDetails Stockholders' Equity - Schedule of Stock Options Issued by the Company (Details) Details 31 false false R32.htm 00000033 - Disclosure - Stockholders' Equity - Schedule of Common Stock Warrant Activity (Details) Sheet http://clearpointneuro.com/role/StockholdersEquityDetails5 Stockholders' Equity - Schedule of Common Stock Warrant Activity (Details) Details 32 false false R33.htm 00000034 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://clearpointneuro.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://clearpointneuro.com/role/StockholdersEquityTables 33 false false All Reports Book All Reports clpt-20200630.xml clpt-20200630.xsd clpt-20200630_cal.xml clpt-20200630_def.xml clpt-20200630_lab.xml clpt-20200630_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 49 0001171520-20-000375-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171520-20-000375-xbrl.zip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�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